labetalol has been researched along with Pregnancy in 314 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to compare the cerebral hemodynamic effects of magnesium sulfate (MgSO4) and labetalol in pre-eclampsia patients with severe features." | 9.69 | Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler. ( Medhat, MM; Mowafy, SMS, 2023) |
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 9.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| "The objectives were to compare the efficacy and safety of intravenous hydralazine and labetalol for acutely lowering severe hypertension in pregnancy." | 9.51 | Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial. ( Bako, B; Dawha, YM; Muhammad, S; Usman, H; Yahya, A; Yekeen, A, 2022) |
| "The purpose is to investigate the influence of nifedipine, labetalol, and magnesium sulfate on blood pressure control, blood coagulation, and maternal and infant outcome in those suffering from pregnancy-induced hypertension (PIH)." | 9.51 | Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension. ( Gu, S; Shao, Y; Zhang, X, 2022) |
| "To compare oral nifedipine and intravenous labetalol in the treatment of acute severe hypertension in pregnancy (SHP)." | 9.41 | Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis. ( Cui, S; Ou, M; Yu, Y; Zhang, F; Zhao, S, 2023) |
| "To compare the change in cerebral perfusion pressure before and after intravenous labetalol vs oral nifedipine in the setting of acute severe hypertension in pregnancy." | 9.34 | Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure. ( Belfort, MA; Clark, SL; Fox, KA; Sangi-Haghpeykar, H; Tolcher, MC, 2020) |
| "to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication." | 9.34 | Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. ( Badr, H; Dawood, R; El-Shamy, E; Emarh, M; Gamal, A; Masood, A; Rezk, M, 2020) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 9.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "To compare the efficacy of intravenous labetalol with oral nifedipine in the treatment of severe hypertension in pregnancy with blood pressure ≥160/110 mm Hg." | 9.30 | IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial. ( Sowjanya, R; Tatapudi, R; Zulfeen, M, 2019) |
| "This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy." | 9.22 | Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. ( Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 9.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 9.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 9.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| "To compare the effectiveness of orally administered nifedipine and intravenously administered labetalol for acute blood pressure control in hypertensive emergency of pregnancy." | 9.17 | Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. ( Sharma, C; Shekhar, S; Thakur, S; Verma, S, 2013) |
| "To compare oral nifedipine with intravenous labetalol in their rapidity to control hypertensive emergencies of pregnancy." | 9.16 | Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. ( Omar, SZ; Raheem, IA; Saaid, R; Tan, PC, 2012) |
| "A total of 150 consecutive pregnant women without proteinuria and with physician-recorded systolic BP of 140-160 mmHg and/or diastolic BP of 90-105 mmHg on two occasions ≥6 h apart between 20 and 38 weeks of gestation were randomly allocated to receive either labetalol or methyldopa (50 patients each) plus standard care (treatment group) or only standard care (50 patients) (control group)." | 9.16 | Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. ( Jabeen, F; Malik, AR; Mir, S; Molvi, SN; Rana, VS, 2012) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 9.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "To evaluate the antihypertensive efficacy of L-arginine (L-Arg) repeated infusions in women affected by gestational hypertension." | 9.12 | Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. ( Blasi, I; Facchinetti, F; Gori, GF; Jasonni, VM; Neri, I, 2006) |
| "To assess the efficacy and safety of nicardipine in comparison to labetalol in the initial management of severe hypertension in pregnancy." | 9.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 9.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 9.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 9.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| "To determine the need for, and efficacy of, treatment with labetalol in women with mild-to-moderate pregnancy induced hypertension (PIH)." | 9.07 | A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1992) |
| "Three hundred women with mild chronic hypertension at 6 to 13 weeks' gestation were randomly allocated to receive either methyldopa or labetalol or be in the control group." | 9.06 | A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. ( Anderson, GD; Mabie, WC; Shamsa, F; Sibai, BM; Villar, MA, 1990) |
| "The effects of labetalol were compared with those of placebo in a multicentre randomized double-blind and prospective study of 152 patients with mild to moderate, non-proteinuric pregnancy-induced hypertension." | 9.06 | The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1989) |
| "Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension." | 9.06 | Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. ( Breart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1988) |
| "Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension." | 9.06 | [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. ( Bréart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1987) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 9.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Labetalol (Trandate; Allen & Hanburys), a combined alpha- and beta-adrenergic blocking agent, was compared with the more commonly used peripheral vasodilator, dihydrallazine (Nepresol; Ciba), each administered as an infusion, in the treatment of severe hypertension in 20 primigravidas at greater than or equal to 32 weeks' gestation." | 9.06 | Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. ( Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987) |
| "Patients with acute pregnancy-related hypertension were randomized to treatment with 200 mg oral labetalol or 10 mg intramuscular hydralazine." | 9.05 | Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. ( Calder, AA; Greer, I; Walker, JJ, 1983) |
| "The effect of intravenous infusion of labetalol and of dihydralazine in increasing doses was compared in 12 women with severe hypertension in pregnancy." | 9.05 | Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. ( Davey, DA; Dommisse, J; Garden, A, 1982) |
| "Twentysix women with pregnancy-induced hypertension have been randomly treated with either labetalol or Aldomet." | 9.05 | Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. ( Broughton Pipkin, F; Lamming, GD; Symonds, EM, 1980) |
| "Oral nifedipine is recommended along with labetalol and hydralazine for treatment of severe hypertension during pregnancy by most authorities." | 8.93 | Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. ( Gupta, N; Kirubakaran, R; Pareek, P; Shekhar, S, 2016) |
| "Labetalol is one of the most commonly used antihypertensive medications for the treatment of hypertension during pregnancy, an increasingly common and leading cause of maternal mortality and morbidity worldwide." | 8.91 | Labetalol for hypertension in pregnancy. ( Cao, V; Koren, G; Magee, LA; Namouz-Haddad, S; von Dadelszen, P, 2015) |
| " Therefore, we analyzed the potency and side effects of two treatment options (nicardipine compared to labetalol) in order to gain insight in improved treatment of severe hypertension during pregnancy and to evaluate the feasibility of a randomised controlled trial." | 8.90 | The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine. ( de Groot, CJ; Meuleman, T; Nooij, LS; Roelofs, R; Visser, S; Vos, P, 2014) |
| "To compare the efficacy of intravenous Labetalol and intravenous Hydralazine in reduction of blood pressure in patients with severe pre-eclampsia." | 8.31 | Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women. ( Husain, S; Hussain, R; Kausar, M, 2023) |
| "The aim of this study was to explore the hemodynamic changes of magnesium sulfate combined with labetalol in the treatment of pregnancy-induced hypertension (PIH) under Doppler uterine ultrasound based on the empirical wavelet transform (EWT) algorithm." | 8.12 | Uterine Ultrasound Doppler Hemodynamics of Magnesium Sulfate Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension Using Empirical Wavelet Transform Algorithm. ( Liu, C; Wang, F; Yin, X, 2022) |
| "To assess whether readmission for hypertension by 6 weeks postpartum differed between patients discharged on nifedipine or labetalol." | 8.12 | Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine. ( Do, SC; Druzin, ML; El-Sayed, YY; Girsen, AI; Herrero, T; Kan, P; Leonard, SA; Lyell, DJ; Panelli, DM, 2022) |
| "The study was performed to assess the response & side effects of injectable Labetalol in the treatment of pregnancy induced severe hypertension." | 7.85 | Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension. ( Ahmed, MU; Akter, FA; Alom, M; Begum, F; Biswas, D; Ferdousi, RA; Hossain, MZ; Nahar, K; Rahman, MM; Razi, RZ, 2017) |
| "Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies." | 7.80 | Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014) |
| "Labetalol and methyldopa are the two antihypertensive drugs most frequently used to control blood pressure for hypertensive disorders of pregnancy." | 7.80 | Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2014) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 7.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "A retrospective study in hypertensive patients treated during pregnancy with nifedipine or labetalol was conducted." | 7.78 | Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. ( Battistoni, GI; Bezzeccheri, V; Cecchi, L; Cecchi, S; Giannubilo, SR; Landi, B; Tranquilli, AL; Vitali, P, 2012) |
| "We investigated the effects of labetalol and pindolol on uterine, placental, and fetal hemodynamics following norepinephrine-induced maternal hypertension in a sheep model of increased placental vascular resistance." | 7.75 | Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension. ( Acharya, G; Alahuhta, S; Erkinaro, T; Haapsamo, M; Kavasmaa, T; Mäkikallio, K; Ohtonen, P; Räsänen, J; Ylikauma, L, 2009) |
| "Our report describes the outcome of a twin pregnancy in a woman who was maintained on tacrolimus after a living related renal transplant." | 7.70 | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. ( Anderson, V; Baqi, N; Hidalgo, G; Kumar, A; Markell, MS; Piecuch, S; Singh, A; Vyas, S, 1999) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 7.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 7.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 7.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "We prospectively studied the effects of oral labetalol therapy in patients with moderate to severe pregnancy induced hypertension (PIH)." | 7.68 | Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. ( Bjornsson, S; Calder, AA; Mahmoud, TZ, 1993) |
| "On the 3rd day after a cesarean section, because of pre-eclampsia, blood pressure was still high, oral labetalol 100 mg with an 8-hour interval was given, followed by 50 mg i." | 7.68 | Hemodynamic collapse following labetalol administration in preeclampsia. ( Beier-Holgersen, R; Olsen, KS, 1992) |
| "8 mg/kg of an intravenous bolus of labetalol on maternal and fetal hemodynamics was investigated in ten women with pregnancy-induced hypertension." | 7.68 | Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms. ( Ekblad, UU; Erkkola, RU; Mäkinen, JI; Pirhonen, JP, 1991) |
| "Pharmacokinetic parameters of oral labetalol were studied in eight women with pregnancy-induced hypertension in the third trimester of pregnancy." | 7.68 | Labetalol pharmacokinetics in pregnancy-induced hypertension. ( Rogers, RC; Sibai, BM; Whybrew, WD, 1990) |
| "The use of captopril in pregnancy has not previously been reported." | 7.66 | Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report. ( Millar, JA; Morrison, N; Wilson, PD, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 7.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "1 Labetalol pharmacokinetics and concentration-effect relationships following intravenous administration have been studied in 10 women during the last trimester of pregnancies complicated by hypertension, in seven of these women postpartum (when normotensive) and in 10 normotensive female volunteers." | 7.66 | Labetalol disposition and concentration-effect relationships during pregnancy. ( Butters, L; Fitzsimons, C; Kelman, AW; Reid, JL; Rubin, PC, 1983) |
| "Labetalol was given to women with hypertension of pregnancy in their last trimester to study its acute effect on circulation and metabolism." | 7.66 | Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy. ( Fredholm, B; Hjemdahl, P; Lewander, R; Lunell, NO; Nisell, H; Nylund, L; Persson, B; Sarby, B; Wager, J, 1982) |
| "1 Eighty-five women with severe hypertension complicating pregnancy were treated with oral labetalol (Trandate)." | 7.66 | The evaluation of labetalol in the treatment of hypertension complicating pregnancy. ( Michael, CA, 1982) |
| "1 Seven women with hypertension of pregnancy were given the combined alpha- and beta-adrenoceptor blocking drug labetalol (50 mg i." | 7.66 | Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy. ( Fredholm, BB; Hjemdahl, P; Lunell, NO; Nisell, H; Persson, B; Wager, J, 1981) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 7.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "Labetalol was given to control blood pressures (BP) with PPE." | 6.87 | Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. ( Li, L; Li, XY; Liu, XW; Sun, CJ; Zhang, WY, 2018) |
| "Labetalol was well tolerated and no significant maternal toxicity was noted." | 6.67 | Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. ( Campbell, DM; Cruickshank, DJ; MacGillivray, I; Robertson, AA, 1992) |
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 6.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 6.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| "Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia." | 6.66 | The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. ( Chauhan, D; Mabie, WC; Ramanathan, J; Ruiz, AG; Sibai, BM, 1988) |
| "Two hundred primigravid women with mild preeclampsia at 26-35 weeks' gestation were randomly allocated to treatment with hospitalization alone or combined with labetalol." | 6.66 | A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. ( Gonzalez, AR; Mabie, WC; Moretti, M; Sibai, BM, 1987) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 5.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| " This study aimed to compare the cerebral hemodynamic effects of magnesium sulfate (MgSO4) and labetalol in pre-eclampsia patients with severe features." | 5.69 | Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler. ( Medhat, MM; Mowafy, SMS, 2023) |
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 5.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| "To explore the regulatory effect of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia." | 5.56 | Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. ( Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020) |
| "Magnesium sulfate was promptly administered on admission to every woman to prevent seizure." | 5.56 | Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. ( Chera-Aree, P; Leetheeragul, J; Sampaojarean, U; Surasereewong, S; Tengtrakulcharoen, P; Wataganara, T, 2020) |
| "The objectives were to compare the efficacy and safety of intravenous hydralazine and labetalol for acutely lowering severe hypertension in pregnancy." | 5.51 | Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial. ( Bako, B; Dawha, YM; Muhammad, S; Usman, H; Yahya, A; Yekeen, A, 2022) |
| "The purpose is to investigate the influence of nifedipine, labetalol, and magnesium sulfate on blood pressure control, blood coagulation, and maternal and infant outcome in those suffering from pregnancy-induced hypertension (PIH)." | 5.51 | Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension. ( Gu, S; Shao, Y; Zhang, X, 2022) |
| "In 14 patients with preeclampsia, 55 hypertensive emergencies were identified (BP >150/95)." | 5.46 | A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. ( Arjona-Berral, JE; Castelo-Branco, C; Duro-Gómez, J; Duro-Gómez, L; Giménez de Azcárete, M; Hernández-Angeles, C; Rodríguez-Marín, AB, 2017) |
| "Recent studies have shown a benefit to more aggressive treatment of mild chronic hypertension to a blood pressure goal of <140/90 with oral labetalol and nifedipine remaining first-line agents." | 5.41 | Cardiac medications in obstetric patients. ( Albert-Stone, E; Davis, MB; Spehar, SM, 2023) |
| "To compare oral nifedipine and intravenous labetalol in the treatment of acute severe hypertension in pregnancy (SHP)." | 5.41 | Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis. ( Cui, S; Ou, M; Yu, Y; Zhang, F; Zhao, S, 2023) |
| "Hypotension is more common after maternal labetalol exposure, regardless of the dosage and route of administration." | 5.38 | Neonatal side effects of maternal labetalol treatment in severe preeclampsia. ( Heida, KY; Hulzebos, CV; Van Veen, TR; Zeeman, GG, 2012) |
| "Pheochromocytoma is a catecholamine-producing tumor but rarely delayingly diagnosed until during pregnancy." | 5.37 | Cardiovascular collapse after labetalol for hypertensive crisis in an undiagnosed pheochromocytoma during cesarean section. ( Huang, CS; Ko, YP; Kuok, CH; Tsai, PS; Yen, CR, 2011) |
| "To compare the change in cerebral perfusion pressure before and after intravenous labetalol vs oral nifedipine in the setting of acute severe hypertension in pregnancy." | 5.34 | Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure. ( Belfort, MA; Clark, SL; Fox, KA; Sangi-Haghpeykar, H; Tolcher, MC, 2020) |
| "The use of labetalol and nifedipine were not related to any significant changes in maternal Doppler, which is reassuring about the safety of these drugs when treating acute severe hypertension in pregnancy." | 5.34 | To study the changes in maternal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension. ( Gainder, S; Prakash, M; Saha, SC; Thakur, M, 2020) |
| "to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication." | 5.34 | Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. ( Badr, H; Dawood, R; El-Shamy, E; Emarh, M; Gamal, A; Masood, A; Rezk, M, 2020) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 5.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "This was a nested cohort study of women with chronic hypertension and a singleton pregnancy recruited to the PANDA (Pregnancy And chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment) study at one of three UK maternity units." | 5.30 | Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study. ( Chappell, LC; Cruickshank, JK; Khalil, A; Mills, C; Myers, JE; Nelson-Piercy, C; Seed, PT; Watt-Coote, I; Webster, LM, 2019) |
| "The use of labetalol and nifedipine were not related to any significant changes in fetal Doppler, which is reassuring about the safety of these drugs when treating acute severe hypertension in pregnancy." | 5.30 | To study the changes in fetal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension. ( Gainder, S; Prakash, M; Saha, SC; Thakur, M, 2019) |
| "To compare the efficacy of intravenous labetalol with oral nifedipine in the treatment of severe hypertension in pregnancy with blood pressure ≥160/110 mm Hg." | 5.30 | IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial. ( Sowjanya, R; Tatapudi, R; Zulfeen, M, 2019) |
| "Fetal tachycardia was present as well." | 5.30 | Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. ( Bergmann, M; Bowman, ML; Smith, JF, 1998) |
| "Twenty mothers with moderate to severe preeclampsia were allocated to labetalol (Trandate) or hydralazine (Apresolin) antihypertensive treatment." | 5.29 | Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment. ( Faxelius, G; Hjertberg, R; Lagercrantz, H, 1993) |
| "The results of the treatment in hypertension with pregnancy by a alpha-beta blocker in 58 women show: the good tolerance of the drug and its lack of teratogenic effect, its quasi-constant efficiency (91%) in hypertension, its benefit repercussion on neonatal weight." | 5.27 | [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. ( Blazquez, G; Gérard, J; Giraud, P; Jeuffroy, A; Lardoux, H; Mounac, M, 1984) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 5.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| " The average daily dosage was 144." | 5.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| "In summary, all commonly prescribed antihypertensives in pregnancy reduce the risk of severe hypertension, but labetalol may also decrease proteinuria/preeclampsia and fetal/newborn death." | 5.22 | Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses. ( Abalos, ED; Bone, JN; Khalil, A; Magee, LA; Omar, S; Prasad, S; Sandhu, A; Singer, J; Vidler, M; von Dadelszen, P, 2022) |
| "This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy." | 5.22 | Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. ( Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022) |
| " In the setting of hypertensive disorders of pregnancy, oral antihypertensive medications should be initiated when systolic blood pressure is greater than 160 mm Hg or when diastolic blood pressure is greater than 110 mm Hg, with the most ideal agents being labetalol or nifedipine." | 5.22 | Hypertensive Disorders of Pregnancy: Common Clinical Conundrums. ( Dotters-Katz, S; Kuller, JA; Lim, SL; Ohamadike, O; Siegel, A; Zemtsov, G, 2022) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 5.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 5.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 5.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| "To compare the effectiveness of orally administered nifedipine and intravenously administered labetalol for acute blood pressure control in hypertensive emergency of pregnancy." | 5.17 | Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. ( Sharma, C; Shekhar, S; Thakur, S; Verma, S, 2013) |
| "To compare oral nifedipine with intravenous labetalol in their rapidity to control hypertensive emergencies of pregnancy." | 5.16 | Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. ( Omar, SZ; Raheem, IA; Saaid, R; Tan, PC, 2012) |
| "A total of 150 consecutive pregnant women without proteinuria and with physician-recorded systolic BP of 140-160 mmHg and/or diastolic BP of 90-105 mmHg on two occasions ≥6 h apart between 20 and 38 weeks of gestation were randomly allocated to receive either labetalol or methyldopa (50 patients each) plus standard care (treatment group) or only standard care (50 patients) (control group)." | 5.16 | Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. ( Jabeen, F; Malik, AR; Mir, S; Molvi, SN; Rana, VS, 2012) |
| "Thirty hypertensive women during the last trimester of pregnancy were divided into four groups: non-diabetic and diabetic women treated with intravenous or oral labetalol." | 5.15 | Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. ( Antunes, NJ; Carvalho, TM; Cavalli, Rde C; Cunha, SP; de Baraldi, CO; Godoy, AL; Lanchote, VL; Marques, MP, 2011) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 5.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "This review (1) summarizes currently recommended medications and dosing strategies for non-emergent HDP treatment, (2) reviews and synthesizes existing literature identified via a comprehensive PubMed search evaluating gestational changes in the maternal pharmacokinetics of commonly prescribed HDP drugs (notably labetalol and nifedipine), and (3) offers insight into the metabolism and clearance mechanisms underlying altered HDP drug pharmacokinetics during pregnancy." | 5.12 | The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions. ( Daubert, MA; Fashe, MM; Garcia, JE; Lee, CR; Loop, MS; Mulrenin, IR; Urrutia, RP, 2021) |
| "To evaluate the antihypertensive efficacy of L-arginine (L-Arg) repeated infusions in women affected by gestational hypertension." | 5.12 | Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. ( Blasi, I; Facchinetti, F; Gori, GF; Jasonni, VM; Neri, I, 2006) |
| "To assess the efficacy and safety of nicardipine in comparison to labetalol in the initial management of severe hypertension in pregnancy." | 5.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 5.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 5.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 5.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| "To determine the need for, and efficacy of, treatment with labetalol in women with mild-to-moderate pregnancy induced hypertension (PIH)." | 5.07 | A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1992) |
| "Three hundred women with mild chronic hypertension at 6 to 13 weeks' gestation were randomly allocated to receive either methyldopa or labetalol or be in the control group." | 5.06 | A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. ( Anderson, GD; Mabie, WC; Shamsa, F; Sibai, BM; Villar, MA, 1990) |
| "The effects of labetalol were compared with those of placebo in a multicentre randomized double-blind and prospective study of 152 patients with mild to moderate, non-proteinuric pregnancy-induced hypertension." | 5.06 | The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1989) |
| "Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension." | 5.06 | Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. ( Breart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1988) |
| "Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension." | 5.06 | [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. ( Bréart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1987) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 5.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Labetalol (Trandate; Allen & Hanburys), a combined alpha- and beta-adrenergic blocking agent, was compared with the more commonly used peripheral vasodilator, dihydrallazine (Nepresol; Ciba), each administered as an infusion, in the treatment of severe hypertension in 20 primigravidas at greater than or equal to 32 weeks' gestation." | 5.06 | Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. ( Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987) |
| "Patients with acute pregnancy-related hypertension were randomized to treatment with 200 mg oral labetalol or 10 mg intramuscular hydralazine." | 5.05 | Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. ( Calder, AA; Greer, I; Walker, JJ, 1983) |
| "The effect of intravenous infusion of labetalol and of dihydralazine in increasing doses was compared in 12 women with severe hypertension in pregnancy." | 5.05 | Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. ( Davey, DA; Dommisse, J; Garden, A, 1982) |
| "Twentysix women with pregnancy-induced hypertension have been randomly treated with either labetalol or Aldomet." | 5.05 | Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. ( Broughton Pipkin, F; Lamming, GD; Symonds, EM, 1980) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| "The present evidence suggests similar efficacy between nifedipine, hydralazine and labetalol in the treatment of severe hypertension in pregnancy." | 4.98 | Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. ( Sequeira, RP; Sridharan, K, 2018) |
| "Oral nifedipine is recommended along with labetalol and hydralazine for treatment of severe hypertension during pregnancy by most authorities." | 4.93 | Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. ( Gupta, N; Kirubakaran, R; Pareek, P; Shekhar, S, 2016) |
| "Labetalol is one of the most commonly used antihypertensive medications for the treatment of hypertension during pregnancy, an increasingly common and leading cause of maternal mortality and morbidity worldwide." | 4.91 | Labetalol for hypertension in pregnancy. ( Cao, V; Koren, G; Magee, LA; Namouz-Haddad, S; von Dadelszen, P, 2015) |
| " Therefore, we analyzed the potency and side effects of two treatment options (nicardipine compared to labetalol) in order to gain insight in improved treatment of severe hypertension during pregnancy and to evaluate the feasibility of a randomised controlled trial." | 4.90 | The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine. ( de Groot, CJ; Meuleman, T; Nooij, LS; Roelofs, R; Visser, S; Vos, P, 2014) |
| "Oral nifedipine, and possibly labetalol and methyldopa, are suitable options for treatment of severe hypertension in pregnancy/postpartum." | 4.90 | Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. ( Firoz, T; Gordon, R; MacDonell, K; Magee, LA; Payne, BA; Vidler, M; von Dadelszen, P, 2014) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "Labetalol has an irreplaceable role in treating Hypertensive disorders of pregnancy (HDP), a common disease during pregnancy with a prevalence of 5." | 4.31 | Physiologically Based Pharmacokinetic Modeling for Multiple Oral Administration Labetalol in Pregnant Women. ( Chen, D; Chen, J; Li, W; Liu, X; Ouyang, D; Song, Y; Wang, W; Wang, X, 2023) |
| "To compare the efficacy of intravenous Labetalol and intravenous Hydralazine in reduction of blood pressure in patients with severe pre-eclampsia." | 4.31 | Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women. ( Husain, S; Hussain, R; Kausar, M, 2023) |
| "The aim of this study was to explore the hemodynamic changes of magnesium sulfate combined with labetalol in the treatment of pregnancy-induced hypertension (PIH) under Doppler uterine ultrasound based on the empirical wavelet transform (EWT) algorithm." | 4.12 | Uterine Ultrasound Doppler Hemodynamics of Magnesium Sulfate Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension Using Empirical Wavelet Transform Algorithm. ( Liu, C; Wang, F; Yin, X, 2022) |
| "A retrospective cohort study of patients with severe peripartum hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mm Hg confirmed within 15 min) to determine whether the effectiveness of blood pressure control using nationally recommended medications (hydralazine, labetalol, nifedipine) differed by race/ethnicity." | 4.12 | Race/ethnicity differences in response to acute antihypertensive treatment of peripartum severe hypertension. ( Greene, NH; Kilpatrick, SJ; Pon, FF, 2022) |
| "To assess whether readmission for hypertension by 6 weeks postpartum differed between patients discharged on nifedipine or labetalol." | 4.12 | Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine. ( Do, SC; Druzin, ML; El-Sayed, YY; Girsen, AI; Herrero, T; Kan, P; Leonard, SA; Lyell, DJ; Panelli, DM, 2022) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| " Carboprost was used less frequently in patients with asthma compared with patients with no asthma (11." | 3.88 | Use of Antihypertensive Medications and Uterotonics During Delivery Hospitalizations in Women With Asthma. ( Ananth, CV; Booker, WA; Cleary, KL; DʼAlton, ME; Friedman, AM; Huang, Y; Siddiq, Z; Wright, JD, 2018) |
| "The study was performed to assess the response & side effects of injectable Labetalol in the treatment of pregnancy induced severe hypertension." | 3.85 | Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension. ( Ahmed, MU; Akter, FA; Alom, M; Begum, F; Biswas, D; Ferdousi, RA; Hossain, MZ; Nahar, K; Rahman, MM; Razi, RZ, 2017) |
| "Hypertensive pregnant women who do not respond to treatment with labetalol to control blood pressure (BP), but require vasodilatory therapy, progress rapidly to severe hypertension." | 3.85 | Longitudinal hemodynamics in acute phase of treatment with labetalol in hypertensive pregnant women to predict need for vasodilatory therapy. ( Bolten, M; Chambers, JB; Kametas, NA; Papastefanou, I; Paraschiv, D; Stott, D, 2017) |
| "To determine whether the incidence of hypotension or adverse fetal heart tracing (FHT) category change differed following antepartum administration of intravenous (IV) labetalol versus hydralazine." | 3.83 | Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low. ( Aghajanian, P; Greene, N; Kilpatrick, SJ; Rodriguez, M; Sharma, KJ, 2016) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| " Antenatally, her blood pressure was controlled with labetalol, and blood tests including serum creatinine were within normal limits for pregnancy." | 3.81 | Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia. ( Kubota-Sjogren, Y; Nelson-Piercy, C, 2015) |
| "Labetalol is frequently prescribed for the treatment of hypertension during pregnancy; however, the influence of pregnancy on labetalol pharmacokinetics is uncertain, with inconsistent findings reported by previous studies." | 3.80 | Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014) |
| "Labetalol and methyldopa are the two antihypertensive drugs most frequently used to control blood pressure for hypertensive disorders of pregnancy." | 3.80 | Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2014) |
| "Labetalol is a drug used in the treatment of hypertensive disorders of pregnancy (HDP)." | 3.80 | Influence of the maternal use of labetalol on the neurogenic mechanism for cerebral autoregulation assessed by means of NIRS. ( Caicedo, A; Lemmers, P; Naulaers, G; Thewissen, L; Van Bel, F; Van Huffel, S; Varon, C, 2014) |
| "We identified a cohort of 9750 patients with outpatient prescriptions for CCBs, methyldopa, or labetalol for pre-existing or gestational hypertension whose days of supply overlapped with delivery; 1226 were exposed to CCBs." | 3.79 | Outpatient calcium-channel blockers and the risk of postpartum haemorrhage: a cohort study. ( Bateman, BT; Ecker, JL; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Palmsten, K; Seely, EW, 2013) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 3.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| " A diagnosis of Raynaud's phenomenon of the nipple was made after she began taking labetalol for pregnancy-induced hypertension." | 3.79 | Raynaud's phenomenon of the nipple associated with labetalol use. ( Cording, V; McGuinness, N, 2013) |
| "Nine mothers were treated with labetalol and/or MgSO4 during pregnancy, three mothers with labetalol, MgSO4 and nifedipine, and 19 mothers with nifedipine only." | 3.79 | Maternal antihypertensive drugs may influence cerebral oxygen extraction in preterm infants during the first days after birth. ( Bos, AF; Kooi, EM; van den Berg, PP; Verhagen, EA, 2013) |
| "A retrospective study in hypertensive patients treated during pregnancy with nifedipine or labetalol was conducted." | 3.78 | Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. ( Battistoni, GI; Bezzeccheri, V; Cecchi, L; Cecchi, S; Giannubilo, SR; Landi, B; Tranquilli, AL; Vitali, P, 2012) |
| "Labetalol is commonly used for control of hypertension in pregnancy." | 3.77 | False-positive amphetamine toxicology screen results in three pregnant women using labetalol. ( Wu, D; Yee, LM, 2011) |
| "To determine the functional development of children born after treatment of mild-to-moderate gestational hypertension with labetalol versus methyldopa, and no antihypertensive treatment." | 3.76 | Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. ( Eskes, TK; Gabreëls, FJ; Pasker-de Jong, PC; Pellegrino, A; van Gelder, MM; Zielhuis, GA, 2010) |
| "We investigated the effects of labetalol and pindolol on uterine, placental, and fetal hemodynamics following norepinephrine-induced maternal hypertension in a sheep model of increased placental vascular resistance." | 3.75 | Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension. ( Acharya, G; Alahuhta, S; Erkinaro, T; Haapsamo, M; Kavasmaa, T; Mäkikallio, K; Ohtonen, P; Räsänen, J; Ylikauma, L, 2009) |
| " In response to moderate hypertension the patient received intravenous labetalol hydrochloride 20 mg." | 3.73 | Inadvertent intrathecal injection of labetalol in a patient undergoing post-partum tubal ligation. ( Balestrieri, PJ; Blank, RS; Grubb, CT; Hamza, MS; Ting, PH, 2005) |
| "These findings demonstrate that agents commonly used for the treatment of hypertensive disease in pregnancy, excluding alpha-methyldopa, have significant direct effects on the feto-placental circulation." | 3.72 | Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. ( Dennedy, MC; Houlihan, DD; Morrison, JJ; Ravikumar, N, 2004) |
| "To research the cerebral hemodynamic effects of labetalol in pregnant women with hypertension." | 3.71 | Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas. ( Allen, JC; Belfort, MA; Dizon-Townson, D; Tooke-Miller, C; Varner, MA, 2002) |
| "In 21 pregnancies complicated by pregnancy-induced hypertension (PIH) which was treated by antihypertensive drugs (labetalol, nifedipine), fetal behavioural recordings (quiet state, C1F; active state, C2F; no coincidence, NOC) and Doppler measurements of blood flow velocity in the umbilical artery (UA) (resistance index, RI) were made on two occasions (27-32 and 33-36 weeks of gestation)." | 3.70 | Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states. ( Bruschettini, PL; Gazzolo, D; Russo, A; Santi, F; Scopesi, F; Visser, GH, 1998) |
| "Two infants with features of severe beta adrenergic blockade, pericardial effusions, and myocardial hypertrophy were born to mothers receiving long term treatment with oral labetalol for hypertension in pregnancy." | 3.70 | Adverse neonatal effects of maternal labetalol treatment. ( Crooks, BN; Deshpande, SA; Hall, C; Milligan, DW; Platt, MP, 1998) |
| "Our report describes the outcome of a twin pregnancy in a woman who was maintained on tacrolimus after a living related renal transplant." | 3.70 | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. ( Anderson, V; Baqi, N; Hidalgo, G; Kumar, A; Markell, MS; Piecuch, S; Singh, A; Vyas, S, 1999) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 3.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 3.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "A single 30 mg intravenous dose of labetalol given 20 minutes prior to cesarean delivery at 35 weeks of gestation for severe pregnancy-induced hypertension was associated with symptoms of beta-adrenergic blockade (hypoglycemia, bradycardia, hypotension) in preterm twins." | 3.69 | Neonatal adrenergic blockade following single dose maternal labetalol administration. ( Bhatt-Mehta, V; Donn, SM; Klarr, JM, 1994) |
| "A 22-year-old woman diagnosed with pheochromocytoma was medically managed at 33 weeks gestation with oral phenoxybenzamine and labetalol until delivery 26 days later." | 3.69 | Phenoxybenzamine placental transfer during the third trimester. ( Santeiro, ML; Stromquist, C; Wyble, L, 1996) |
| "The effect of intravenously-administered labetalol (1 mg/kg) on uterine and fetal hemodynamics and fetal cardiac function was studied in 13 women with pregnancy-induced hypertension." | 3.68 | Effect of labetalol infusion on uterine and fetal hemodynamics and fetal cardiac function. ( Jouppila, P; Räsänen, J, 1993) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 3.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "We prospectively studied the effects of oral labetalol therapy in patients with moderate to severe pregnancy induced hypertension (PIH)." | 3.68 | Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. ( Bjornsson, S; Calder, AA; Mahmoud, TZ, 1993) |
| "Forty eight neonates, born to mothers suffering from pregnancy induced hypertension and receiving labetalol for control of blood pressure, were studied for the possible adverse effects of the drug." | 3.68 | Effects of maternal labetalol on the newborn infant. ( Deorari, AK; Munshi, UK; Paul, VK; Singh, M, 1992) |
| "On the 3rd day after a cesarean section, because of pre-eclampsia, blood pressure was still high, oral labetalol 100 mg with an 8-hour interval was given, followed by 50 mg i." | 3.68 | Hemodynamic collapse following labetalol administration in preeclampsia. ( Beier-Holgersen, R; Olsen, KS, 1992) |
| "The maternal-fetal disposition of labetalol, a combined alpha-1 and beta adrenergic blocker, and its pharmacodynamics in pregnancy are not well understood." | 3.68 | Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ( Axelson, JE; Hall, C; Rurak, DW; Wright, MR; Yeleswaram, K, 1992) |
| "8 mg/kg of an intravenous bolus of labetalol on maternal and fetal hemodynamics was investigated in ten women with pregnancy-induced hypertension." | 3.68 | Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms. ( Ekblad, UU; Erkkola, RU; Mäkinen, JI; Pirhonen, JP, 1991) |
| "Pharmacokinetic parameters of oral labetalol were studied in eight women with pregnancy-induced hypertension in the third trimester of pregnancy." | 3.68 | Labetalol pharmacokinetics in pregnancy-induced hypertension. ( Rogers, RC; Sibai, BM; Whybrew, WD, 1990) |
| " The mother had been treated with adequate doses of labetalol because of pregnancy-induced hypertension and her plasma concentration was found to be 89 micrograms/l one day after delivery." | 3.67 | Half-life of maternal labetalol in a premature infant. ( Geven, W; Haraldsson, A, 1989) |
| "The transfer of labetalol into human breast milk and amniotic fluid was studied in women with pregnancy hypertension." | 3.67 | Transfer of labetalol into amniotic fluid and breast milk in lactating women. ( Kulas, J; Lunell, NO; Rane, A, 1985) |
| "The use of captopril in pregnancy has not previously been reported." | 3.66 | Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report. ( Millar, JA; Morrison, N; Wilson, PD, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 3.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "1 Labetalol pharmacokinetics and concentration-effect relationships following intravenous administration have been studied in 10 women during the last trimester of pregnancies complicated by hypertension, in seven of these women postpartum (when normotensive) and in 10 normotensive female volunteers." | 3.66 | Labetalol disposition and concentration-effect relationships during pregnancy. ( Butters, L; Fitzsimons, C; Kelman, AW; Reid, JL; Rubin, PC, 1983) |
| "Labetalol was given to women with hypertension of pregnancy in their last trimester to study its acute effect on circulation and metabolism." | 3.66 | Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy. ( Fredholm, B; Hjemdahl, P; Lewander, R; Lunell, NO; Nisell, H; Nylund, L; Persson, B; Sarby, B; Wager, J, 1982) |
| "1 Eighty-five women with severe hypertension complicating pregnancy were treated with oral labetalol (Trandate)." | 3.66 | The evaluation of labetalol in the treatment of hypertension complicating pregnancy. ( Michael, CA, 1982) |
| "1 Seven women with hypertension of pregnancy were given the combined alpha- and beta-adrenoceptor blocking drug labetalol (50 mg i." | 3.66 | Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy. ( Fredholm, BB; Hjemdahl, P; Lunell, NO; Nisell, H; Persson, B; Wager, J, 1981) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 3.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "Hypertension during pregnancy is associated with a higher risk of cardiovascular disease and kidney failure." | 3.01 | Evaluation and Management of Hypertensive Disorders of Pregnancy. ( Bajpai, D; Dumanski, S; Popa, C; Shah, S; Verma, P, 2023) |
| "Labetalol was given to control blood pressures (BP) with PPE." | 2.87 | Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. ( Li, L; Li, XY; Liu, XW; Sun, CJ; Zhang, WY, 2018) |
| "Labetalol was well tolerated and no significant maternal toxicity was noted." | 2.67 | Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. ( Campbell, DM; Cruickshank, DJ; MacGillivray, I; Robertson, AA, 1992) |
| "Normal pregnancy is a complex and dynamic process that requires significant adaptation from the maternal system." | 2.66 | Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond. ( Doherty, A; Kingdom, JC; McLaughlin, K, 2020) |
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 2.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 2.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| "Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia." | 2.66 | The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. ( Chauhan, D; Mabie, WC; Ramanathan, J; Ruiz, AG; Sibai, BM, 1988) |
| "Two hundred primigravid women with mild preeclampsia at 26-35 weeks' gestation were randomly allocated to treatment with hospitalization alone or combined with labetalol." | 2.66 | A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. ( Gonzalez, AR; Mabie, WC; Moretti, M; Sibai, BM, 1987) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Preeclampsia is characterized by blood pressure greater than 140/90 mmHg in the second half of pregnancy." | 2.55 | Pathophysiology and Current Clinical Management of Preeclampsia. ( Amaral, LM; LaMarca, B; Owens, M; Wallace, K, 2017) |
| "Women with chronic hypertension are at significant risk for maternal and fetal morbidity and mortality, yet it remains unclear whether antihypertensive treatment during pregnancy lowers these risks." | 2.55 | New Evidence in the Management of Chronic Hypertension in Pregnancy. ( August, P; Podymow, T, 2017) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | 2.43 | Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| "While nitroprusside is commonly used to treat severe hypertension, it is an extremely toxic drug that should only be used in rare circumstances." | 2.41 | The diagnosis and management of hypertensive crises. ( Marik, PE; Varon, J, 2000) |
| "The etiology of preeclampsia is still unknown." | 2.41 | Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. ( Bolte, AC; Dekker, GA; van Geijn, HP, 2001) |
| " These drugs must be administered parenterally and have a half-life of only a few minutes." | 2.40 | Clinical pharmacokinetics of vasodilators. Part II. ( Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998) |
| "Hypertension in pregnancy has implications for both maternal and fetal welfare." | 2.37 | Hypertension in pregnancy. Pathophysiology and management. ( Lubbe, WF, 1984) |
| "Labetalol is a unique antihypertensive agent which induces both alpha- and beta-blockade." | 2.37 | Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. ( Lund-Johansen, P, 1984) |
| "Labetalol is a unique antihypertensive agent which is a competitive peripheral antagonist at both alpha- and beta-adrenoceptor sites." | 2.37 | Current status of labetalol, the first alpha- and beta-blocking agent. ( Kanto, JH, 1985) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 1.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| "The HDP spectrum includes gestational hypertension (HTN), preeclampsia, eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, chronic HTN, and chronic HTN with superimposed preeclampsia." | 1.72 | Hypertensive Conditions: Hypertensive Disorders in Pregnancy. ( Daly, PL; Goodwin, ET; Kipnis, CM; Smith, DK, 2022) |
| "Severe hypertension is a risk factor for sustained hypertension after pregnancy." | 1.62 | Severe hypertension in pregnancy. ( Damodaram, M; Frise, C; Wiles, K, 2021) |
| "To explore the regulatory effect of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia." | 1.56 | Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. ( Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020) |
| "Magnesium sulfate was promptly administered on admission to every woman to prevent seizure." | 1.56 | Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. ( Chera-Aree, P; Leetheeragul, J; Sampaojarean, U; Surasereewong, S; Tengtrakulcharoen, P; Wataganara, T, 2020) |
| "Labetalol treatment was appropriately initiated in many cases; however, protocol adherence could greatly improve." | 1.48 | Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms. ( Duong, J; Haring, A; Kuhlmann, Z; O'brien, L; Winterton, T, 2018) |
| "Preeclampsia is characterised by systemic endothelial cell dysfunction thought to be triggered by toxic/dangerous factors from the placenta, including placental extracellular vesicles (EVs)." | 1.46 | Treating normal early gestation placentae with preeclamptic sera produces extracellular micro and nano vesicles that activate endothelial cells. ( Chamley, LW; Chen, Q; Stone, PR; Tong, M; Wise, MR; Xiao, F; Xiao, X; Zhao, M, 2017) |
| "In 14 patients with preeclampsia, 55 hypertensive emergencies were identified (BP >150/95)." | 1.46 | A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. ( Arjona-Berral, JE; Castelo-Branco, C; Duro-Gómez, J; Duro-Gómez, L; Giménez de Azcárete, M; Hernández-Angeles, C; Rodríguez-Marín, AB, 2017) |
| "Labetalol was the commonest antihypertensive used." | 1.43 | Survey of healthcare professionals regarding adjustment of antihypertensive medication(s) in the postnatal period in women with hypertensive disorders of pregnancy. ( Cairns, AE; Leeson, P; Mackillop, L; McManus, RJ; Tucker, KL, 2016) |
| "Hypocalcemia is a complication that must be monitored when a treatment with high doses of intravenous magnesium sulphate is introduced." | 1.40 | [Electrolyte disorders in preeclampsia. A case report]. ( Bodenmann Gobin, P; Ducry, J; Gobin, N; Portmann, L; Vial, Y; Vogt, B, 2014) |
| "During hypoxemia, fetal heart rate increased to baseline in the pindolol group and pulmonary vascular impedances increased in the labetalol group, with no changes in fetal cardiac outputs." | 1.39 | Fetal cardiac function after labetalol or pindolol for maternal hypertension in a sheep model of increased placental vascular resistance. ( Acharya, G; Erkinaro, T; Haapsamo, M; Kavasmaa, T; Mäkikallio, K; Räsänen, J, 2013) |
| "Hypotension is more common after maternal labetalol exposure, regardless of the dosage and route of administration." | 1.38 | Neonatal side effects of maternal labetalol treatment in severe preeclampsia. ( Heida, KY; Hulzebos, CV; Van Veen, TR; Zeeman, GG, 2012) |
| "Postpartum preeclampsia/eclampsia is the presence of hypertension and proteinuria, with or without seizures, occurring up to 4 weeks after delivery." | 1.37 | Postpartum preeclampsia: emergency department presentation and management. ( Abbott, J; Bakes, K; Withers, E; Yancey, LM, 2011) |
| "Pheochromocytoma is a catecholamine-producing tumor but rarely delayingly diagnosed until during pregnancy." | 1.37 | Cardiovascular collapse after labetalol for hypertensive crisis in an undiagnosed pheochromocytoma during cesarean section. ( Huang, CS; Ko, YP; Kuok, CH; Tsai, PS; Yen, CR, 2011) |
| " In the present investigation, a method for the analysis of labetalol stereoisomers in human plasma was developed and applied to pharmacokinetic studies." | 1.35 | Stereoselective analysis of labetalol in human plasma by LC-MS/MS: application to pharmacokinetics. ( Baraldi, Cde O; Carvalho, TM; Cavalli, Rde C; Da Cunha, SP; Lanchote, VL; Marques, MP, 2009) |
| "Posterior reversible encephalopathy syndrome is a reversible syndrome characterized by headache, seizures, altered mentation, and loss of vision associated with white matter changes on imaging." | 1.35 | Late postpartum preeclampsia with posterior reversible encephalopathy syndrome. ( Kauntia, R; Pandit, VR; Prabhu, MM; Seshadri, S; Valsalan, R, 2009) |
| "She also had retinal hemorrhages in both eyes and a hemorrhagic infarct in the left occipital lobe that resulted in a permanent right homonymous hemianopia and a persistently depressed acuity of 20/100 OS." | 1.33 | Permanent visual deficits secondary to the HELLP syndrome. ( Ayazifar, M; Murphy, MA, 2005) |
| " This report does not suggest the routine use of low-dose spinal anesthesia without supplements, but illustrates the wide variability in dosage and sensitivity to spinal anesthetics, and suggests that further research is needed in this area, particularly in morbidly obese parturients." | 1.32 | Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications. ( Pan, PH; Reyes, M, 2004) |
| "Fetal tachycardia was present as well." | 1.30 | Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. ( Bergmann, M; Bowman, ML; Smith, JF, 1998) |
| "In women with severe preeclampsia, significant increases in mean arterial pressures (MAP) are common after rapid induction of general anesthesia (GA) and tracheal intubation." | 1.30 | Changes in maternal middle cerebral artery blood flow velocity associated with general anesthesia in severe preeclampsia. ( Angel, JJ; Bush, AJ; Lawson, P; Ramanathan, J; Sibai, B, 1999) |
| "Pretreatment with labetalol 10(-4) mol/l inhibited the transient increase in perfusion pressure induced by norepinephrine 3 x 10(-5) mol/l." | 1.29 | The effects of dihydralazine, labetalol and magnesium sulphate on the isolated, perfused human placental cotyledon. ( Forman, A; Gregersen, H; Petersen, OB; Skajaa, K; Svane, D, 1994) |
| "To assess the influence of intrauterine growth retardation on heart rate (HR) and HR variability during sleep, we performed polygraphic recordings in 10 small-for-gestational age (SGA) and 16 appropriate-for-gestational age (AGA) newborns." | 1.29 | Heart rate and heart rate variability during sleep in small-for-gestational age newborns. ( Clairambault, J; Curzi-Dascalova, L; Eiselt, M; Kauffmann, F; Médigue, C; Peirano, P; Spassov, L, 1994) |
| "Labetalol has been previously shown to cause significant maternal and fetal metabolic effects in pregnant sheep after maternal administration." | 1.29 | Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ( Abbott, FS; Axelson, JE; Doroudian, A; Hall, C; Kwan, E; Rurak, DW; Wright, MR; Yeleswaram, K, 1993) |
| "Twenty mothers with moderate to severe preeclampsia were allocated to labetalol (Trandate) or hydralazine (Apresolin) antihypertensive treatment." | 1.29 | Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment. ( Faxelius, G; Hjertberg, R; Lagercrantz, H, 1993) |
| "Labetalol has been advocated to rapidly decrease blood pressure in preeclamptic women and to blunt the hemodynamic response to tracheal intubation." | 1.28 | Maternal and fetal effects of labetalol in pregnant ewes. ( Dewan, DM; Eisenach, JC; Mandell, G, 1991) |
| "Labetalol was extracted from the samples using ethyl acetate and then partitioned into dilute phosphoric acid." | 1.28 | Sensitive microbore high-performance liquid chromatographic assay for labetalol in the biological fluids of pregnant sheep. ( Axelson, JE; Rurak, DW; Yeleswaram, K, 1991) |
| "Hydralazine failed to inhibit responses to any of the agonists tested in the fetal and maternal arteries." | 1.28 | Effects of vasodilators on isolated human uteroplacental arteries. ( Allen, J; Forman, A; Maigaard, S; Skajaa, K, 1991) |
| "The results of the treatment in hypertension with pregnancy by a alpha-beta blocker in 58 women show: the good tolerance of the drug and its lack of teratogenic effect, its quasi-constant efficiency (91%) in hypertension, its benefit repercussion on neonatal weight." | 1.27 | [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. ( Blazquez, G; Gérard, J; Giraud, P; Jeuffroy, A; Lardoux, H; Mounac, M, 1984) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 1.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| " The average daily dosage was 144." | 1.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| "5." | 1.27 | The effect of labetalol on contractility of human myometrial preparations. ( Angilivilayil, C; Ibrahim, M; Lunell, NO; Moberger, B; Thulesius, O, 1987) |
| " From measurements of the total plasma radioactivity it was shown that labetalol was well absorbed by all the species." | 1.26 | Metabolism of labetalol by animals and man. ( Bland, R; Hopkins, R; Martin, LE, 1976) |
| " It was not possible to saturate the melanin of the cat and dog eye even with prolonged dosing with labetalol." | 1.26 | Affinity of labetalol for ocular melanin. ( Cook, J; Harrison, C; Martin, LE; Poynter, D, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 72 (22.93) | 18.7374 |
| 1990's | 56 (17.83) | 18.2507 |
| 2000's | 38 (12.10) | 29.6817 |
| 2010's | 103 (32.80) | 24.3611 |
| 2020's | 45 (14.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wiles, K | 1 |
| Damodaram, M | 1 |
| Frise, C | 1 |
| Mulrenin, IR | 1 |
| Garcia, JE | 1 |
| Fashe, MM | 1 |
| Loop, MS | 1 |
| Daubert, MA | 1 |
| Urrutia, RP | 1 |
| Lee, CR | 1 |
| Ashworth, D | 2 |
| Battersby, C | 2 |
| Green, M | 2 |
| Hardy, P | 2 |
| McManus, RJ | 4 |
| Cluver, C | 1 |
| Chappell, LC | 6 |
| Bone, JN | 1 |
| Sandhu, A | 1 |
| Abalos, ED | 1 |
| Khalil, A | 2 |
| Singer, J | 6 |
| Prasad, S | 1 |
| Omar, S | 1 |
| Vidler, M | 2 |
| von Dadelszen, P | 9 |
| Magee, LA | 12 |
| Wu, HZ | 1 |
| Cheng, Y | 1 |
| Yu, D | 1 |
| Li, JB | 1 |
| Jiang, YF | 1 |
| Zhu, ZN | 1 |
| Ohamadike, O | 1 |
| Lim, SL | 1 |
| Siegel, A | 1 |
| Zemtsov, G | 1 |
| Kuller, JA | 1 |
| Dotters-Katz, S | 1 |
| Dublin, S | 1 |
| Idu, A | 1 |
| Avalos, LA | 1 |
| Cheetham, TC | 1 |
| Easterling, TR | 1 |
| Chen, L | 2 |
| Holt, VL | 1 |
| Nance, N | 1 |
| Bider-Canfield, Z | 1 |
| Neugebauer, RS | 1 |
| Reynolds, K | 1 |
| Badon, SE | 1 |
| Shortreed, SM | 1 |
| Muhammad, S | 1 |
| Usman, H | 1 |
| Dawha, YM | 1 |
| Yahya, A | 1 |
| Yekeen, A | 1 |
| Bako, B | 1 |
| Liu, C | 1 |
| Wang, F | 2 |
| Yin, X | 1 |
| Rednic, R | 1 |
| Marcovici, I | 1 |
| Dragoi, R | 1 |
| Pinzaru, I | 1 |
| Dehelean, CA | 1 |
| Tomescu, M | 1 |
| Arnautu, DA | 1 |
| Craina, M | 1 |
| Gluhovschi, A | 1 |
| Valcovici, M | 1 |
| Manea, A | 1 |
| Greene, NH | 1 |
| Pon, FF | 1 |
| Kilpatrick, SJ | 5 |
| Do, SC | 1 |
| Leonard, SA | 1 |
| Kan, P | 1 |
| Panelli, DM | 1 |
| Girsen, AI | 1 |
| Lyell, DJ | 1 |
| El-Sayed, YY | 1 |
| Druzin, ML | 1 |
| Herrero, T | 1 |
| van de Vusse, D | 1 |
| Mian, P | 1 |
| Schoenmakers, S | 1 |
| Flint, RB | 1 |
| Visser, W | 1 |
| Allegaert, K | 1 |
| Versmissen, J | 1 |
| Wautlet, CK | 1 |
| Hoffman, MC | 1 |
| Shao, Y | 1 |
| Gu, S | 1 |
| Zhang, X | 1 |
| Kipnis, CM | 1 |
| Daly, PL | 1 |
| Goodwin, ET | 1 |
| Smith, DK | 1 |
| Kim, MK | 1 |
| Choe, KR | 1 |
| Jeong, DE | 1 |
| Lee, KN | 1 |
| Cho, I | 1 |
| Kim, HJ | 1 |
| Park, JY | 1 |
| Trahan, MJ | 1 |
| Plourde, M | 1 |
| Wou, K | 1 |
| Huroy, M | 1 |
| Itani, R | 1 |
| Pavilanis, A | 1 |
| Flannery, A | 1 |
| Haas, S | 1 |
| Aucoin, G | 1 |
| Monast, PO | 1 |
| Koolian, M | 1 |
| Hassan, N | 1 |
| Suarthana, E | 1 |
| Daskalopoulou, SS | 1 |
| Malhamé, I | 1 |
| Kou, X | 1 |
| Yang, J | 1 |
| Spehar, SM | 1 |
| Albert-Stone, E | 1 |
| Davis, MB | 1 |
| Mowafy, SMS | 1 |
| Medhat, MM | 1 |
| Song, Y | 1 |
| Wang, W | 1 |
| Liu, X | 1 |
| Chen, J | 1 |
| Chen, D | 1 |
| Wang, X | 1 |
| Li, W | 1 |
| Ouyang, D | 1 |
| S, D | 1 |
| Novri, DA | 1 |
| Hamidy, Y | 1 |
| Savira, M | 1 |
| Cífková, R | 1 |
| Ou, M | 1 |
| Zhang, F | 1 |
| Cui, S | 1 |
| Zhao, S | 1 |
| Yu, Y | 1 |
| Bajpai, D | 1 |
| Popa, C | 1 |
| Verma, P | 1 |
| Dumanski, S | 1 |
| Shah, S | 1 |
| Kausar, M | 1 |
| Husain, S | 1 |
| Hussain, R | 1 |
| Bick, D | 1 |
| Leighton, L | 1 |
| Maher, A | 1 |
| Moakes, C | 1 |
| Morris, RK | 1 |
| Nelson-Piercy, C | 5 |
| Sparkes, J | 1 |
| Rivero-Arias, O | 1 |
| Webb, A | 1 |
| Wilson, H | 1 |
| Myers, J | 2 |
| Peng, Z | 1 |
| Zhang, J | 1 |
| Xiao, Y | 1 |
| Dong, W | 1 |
| Webster, LM | 3 |
| Reed, K | 1 |
| Myers, JE | 3 |
| Burns, A | 1 |
| Gupta, P | 1 |
| Patel, P | 1 |
| Wiesender, C | 1 |
| Seed, PT | 2 |
| Rey, E | 5 |
| Asztalos, E | 3 |
| Hutton, E | 3 |
| Helewa, M | 4 |
| Lee, T | 4 |
| Logan, AG | 5 |
| Ganzevoort, W | 1 |
| Welch, R | 3 |
| Thornton, JG | 3 |
| Lay-Flurrie, S | 1 |
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Wu, Y | 1 |
| Wang, DJ | 1 |
| Zhang, Y | 1 |
| Zhang, YX | 1 |
| Zhang, R | 1 |
| Tolcher, MC | 1 |
| Fox, KA | 1 |
| Sangi-Haghpeykar, H | 1 |
| Clark, SL | 2 |
| Belfort, MA | 3 |
| Thakur, M | 2 |
| Gainder, S | 3 |
| Saha, SC | 3 |
| Prakash, M | 2 |
| Chera-Aree, P | 1 |
| Tengtrakulcharoen, P | 1 |
| Leetheeragul, J | 1 |
| Sampaojarean, U | 1 |
| Surasereewong, S | 1 |
| Wataganara, T | 1 |
| Cluver, CA | 1 |
| Herbst, P | 1 |
| Griffith-Richards, S | 1 |
| Hassan, M | 1 |
| Allwood, B | 1 |
| Rezk, M | 1 |
| Emarh, M | 1 |
| Masood, A | 1 |
| Dawood, R | 1 |
| El-Shamy, E | 1 |
| Gamal, A | 1 |
| Badr, H | 1 |
| Doherty, A | 1 |
| McLaughlin, K | 1 |
| Kingdom, JC | 1 |
| Miremberg, H | 1 |
| Rubinchik-Stern, M | 1 |
| Lurie, O | 1 |
| Bar, J | 1 |
| Kovo, M | 1 |
| Martin, C | 1 |
| Pappas, J | 1 |
| Johns, K | 1 |
| Figueroa, H | 1 |
| Balli, K | 1 |
| Yao, R | 1 |
| Yoon, SW | 1 |
| Choi, GJ | 1 |
| Seong, HK | 1 |
| Lee, MJ | 1 |
| Kang, H | 1 |
| Woolston, E | 1 |
| Tang, Y | 1 |
| Azizi, S | 1 |
| Kando, I | 1 |
| Chamley, L | 1 |
| Stone, P | 1 |
| Chen, Q | 2 |
| Mulder, EG | 1 |
| Ghossein-Doha, C | 1 |
| Cauffman, E | 1 |
| Lopes van Balen, VA | 1 |
| Schiffer, VMMM | 1 |
| Alers, RJ | 1 |
| Oben, J | 1 |
| Smits, L | 1 |
| van Kuijk, SMJ | 1 |
| Spaanderman, MEA | 1 |
| Xiang, X | 1 |
| Zhao, N | 1 |
| Zhou, Z | 1 |
| Mullan, SJ | 1 |
| Vricella, LK | 1 |
| Edwards, AM | 1 |
| Powel, JE | 1 |
| Ong, SK | 1 |
| Li, X | 1 |
| Tomlinson, TM | 1 |
| Bordlee, JW | 1 |
| Beakley, BD | 1 |
| Mody, R | 1 |
| McConville, AP | 1 |
| Weed, JT | 1 |
| McClure, BP | 1 |
| Foldes, PJ | 1 |
| Ma, JG | 1 |
| Kaye, AD | 1 |
| Eskander, JP | 1 |
| Duan, L | 2 |
| Ng, A | 2 |
| Chen, W | 2 |
| Spencer, HT | 2 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Lee, MS | 2 |
| Sharma, KJ | 2 |
| Xiao, X | 1 |
| Xiao, F | 1 |
| Zhao, M | 1 |
| Tong, M | 1 |
| Wise, MR | 1 |
| Stone, PR | 1 |
| Chamley, LW | 1 |
| Duro-Gómez, J | 1 |
| Rodríguez-Marín, AB | 1 |
| Giménez de Azcárete, M | 1 |
| Duro-Gómez, L | 1 |
| Hernández-Angeles, C | 1 |
| Arjona-Berral, JE | 1 |
| Castelo-Branco, C | 1 |
| Fitton, CA | 1 |
| Steiner, MFC | 1 |
| Aucott, L | 1 |
| Pell, JP | 1 |
| Mackay, DF | 1 |
| Fleming, M | 1 |
| McLay, JS | 1 |
| Amaral, LM | 1 |
| Wallace, K | 1 |
| Owens, M | 1 |
| LaMarca, B | 1 |
| Podymow, T | 1 |
| August, P | 1 |
| Dong, XY | 1 |
| Bai, CB | 1 |
| Nao, JF | 1 |
| Akter, FA | 1 |
| Nahar, K | 1 |
| Rahman, MM | 1 |
| Ferdousi, RA | 1 |
| Ahmed, MU | 1 |
| Begum, F | 1 |
| Biswas, D | 1 |
| Alom, M | 1 |
| Hossain, MZ | 1 |
| Razi, RZ | 1 |
| Wang, Y | 1 |
| Shi, D | 1 |
| Mills, C | 1 |
| Watt-Coote, I | 1 |
| Cruickshank, JK | 1 |
| Lee, R | 1 |
| Carr, D | 1 |
| Shawkat, E | 1 |
| Mistry, H | 1 |
| Chmiel, C | 1 |
| Webster, L | 1 |
| Chappell, L | 1 |
| Johnstone, ED | 1 |
| Kanawati, S | 1 |
| Nassour, A | 1 |
| Sun, CJ | 1 |
| Li, L | 1 |
| Li, XY | 1 |
| Zhang, WY | 1 |
| Liu, XW | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Booker, WA | 1 |
| Siddiq, Z | 1 |
| Huang, Y | 1 |
| Ananth, CV | 1 |
| Wright, JD | 1 |
| Cleary, KL | 1 |
| DʼAlton, ME | 1 |
| Friedman, AM | 1 |
| Sridharan, K | 1 |
| Sequeira, RP | 1 |
| Webb, AJ | 1 |
| O'brien, L | 1 |
| Duong, J | 1 |
| Winterton, T | 1 |
| Haring, A | 1 |
| Kuhlmann, Z | 1 |
| Zulfeen, M | 1 |
| Tatapudi, R | 1 |
| Sowjanya, R | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Patel, V | 1 |
| Ramachandran, B | 1 |
| Omar, I | 1 |
| Lemoine, ER | 1 |
| Karumanchi, SA | 1 |
| Easterling, T | 1 |
| Mundle, S | 1 |
| Bracken, H | 1 |
| Parvekar, S | 1 |
| Mool, S | 1 |
| Shochet, T | 1 |
| Winikoff, B | 1 |
| Alexander, JM | 1 |
| Wilson, KL | 1 |
| Caicedo, A | 2 |
| Thewissen, L | 3 |
| Naulaers, G | 3 |
| Lemmers, P | 3 |
| van Bel, F | 3 |
| Van Huffel, S | 2 |
| Arulkumaran, N | 1 |
| Lightstone, L | 1 |
| Bateman, BT | 2 |
| Hernandez-Diaz, S | 2 |
| Huybrechts, KF | 2 |
| Palmsten, K | 1 |
| Mogun, H | 2 |
| Ecker, JL | 1 |
| Seely, EW | 2 |
| Fischer, MA | 2 |
| Shekhar, S | 2 |
| Sharma, C | 1 |
| Thakur, S | 1 |
| Verma, S | 1 |
| Xie, RH | 2 |
| Guo, Y | 2 |
| Krewski, D | 2 |
| Mattison, D | 2 |
| Nerenberg, K | 2 |
| Walker, MC | 2 |
| Wen, SW | 2 |
| Fischer, JH | 1 |
| Sarto, GE | 1 |
| Hardman, J | 1 |
| Endres, L | 1 |
| Jenkins, TM | 1 |
| Jeong, H | 1 |
| Geller, S | 1 |
| Deyo, K | 1 |
| Fischer, PA | 1 |
| Rodvold, KA | 1 |
| Bodenmann Gobin, P | 1 |
| Gobin, N | 1 |
| Ducry, J | 1 |
| Portmann, L | 1 |
| Vial, Y | 1 |
| Vogt, B | 1 |
| Gogia, V | 1 |
| Sharma, S | 1 |
| Deka, D | 1 |
| Dadhwal, V | 1 |
| Venkatesh, P | 1 |
| Nooij, LS | 1 |
| Visser, S | 1 |
| Meuleman, T | 1 |
| Vos, P | 1 |
| Roelofs, R | 1 |
| de Groot, CJ | 1 |
| Varon, C | 1 |
| Firoz, T | 1 |
| MacDonell, K | 1 |
| Payne, BA | 1 |
| Gordon, R | 1 |
| Chattopadhyay, S | 1 |
| Das, A | 1 |
| Pahari, S | 1 |
| Castiella, A | 1 |
| Iglesias, U | 1 |
| Zapata, E | 1 |
| Zubiaurre, L | 1 |
| Iribarren, A | 1 |
| Gangooly, S | 1 |
| Muttukrishna, S | 1 |
| Jauniaux, E | 1 |
| Vadhera, RB | 1 |
| Simon, M | 1 |
| Thomas, B | 1 |
| Abdul Rouf, PV | 1 |
| El Kassem, W | 1 |
| Al Hail, M | 1 |
| Stewart, D | 1 |
| Tharannum, A | 1 |
| Ahmed, A | 1 |
| Al Saadi, M | 1 |
| Rolfes, L | 1 |
| de Swart-Ruijter, I | 1 |
| van Hunsel, F | 1 |
| Shi, Q | 1 |
| Leng, W | 1 |
| Yao, Q | 1 |
| Mi, C | 1 |
| Xing, A | 1 |
| Morris, R | 1 |
| Sunesara, I | 1 |
| Darby, M | 1 |
| Novotny, S | 1 |
| Kiprono, L | 1 |
| Bautista, L | 1 |
| Sawardecker, S | 1 |
| Bofill, J | 1 |
| Anderson, B | 1 |
| Martin, JN | 1 |
| Namouz-Haddad, S | 1 |
| Cao, V | 1 |
| Koren, G | 5 |
| Gómez Torrijos, E | 1 |
| García Rodríguez, C | 1 |
| Sánchez Caminero, MP | 1 |
| Castro Jiménez, A | 1 |
| García Rodríguez, R | 1 |
| Feo-Brito, F | 1 |
| Gupta, N | 1 |
| Kirubakaran, R | 1 |
| Pareek, P | 1 |
| Ross, S | 3 |
| Murphy, KE | 2 |
| Menzies, J | 2 |
| Sanchez, J | 2 |
| Gafni, A | 3 |
| Gruslin, A | 3 |
| Lee, SK | 3 |
| Ganzevoort, JW | 2 |
| Moutquin, JM | 3 |
| Clark, SM | 1 |
| Dunn, HE | 1 |
| Hankins, GD | 1 |
| Sibai, BM | 8 |
| Olson-Chen, C | 1 |
| Seligman, NS | 1 |
| Kubota-Sjogren, Y | 1 |
| Abreo, A | 1 |
| Greene, N | 2 |
| Melsop, K | 1 |
| Peterson, N | 1 |
| Shields, LE | 1 |
| Main, EK | 1 |
| Rodriguez, M | 1 |
| Aghajanian, P | 1 |
| Richter, AE | 1 |
| Schat, TE | 1 |
| Van Braeckel, KN | 1 |
| Scherjon, SA | 1 |
| Bos, AF | 2 |
| Kooi, EM | 2 |
| Muthyala, T | 1 |
| Bagga, R | 1 |
| Saha, PK | 1 |
| Lal, V | 1 |
| Singh, P | 1 |
| Kaushik, S | 1 |
| Pistorius, L | 1 |
| Baerts, W | 1 |
| Stott, D | 2 |
| Bolten, M | 2 |
| Salman, M | 1 |
| Paraschiv, D | 2 |
| Douiri, A | 1 |
| Kametas, NA | 2 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Maeda, A | 1 |
| Shi, DD | 1 |
| Yang, FZ | 1 |
| Zhou, L | 1 |
| Wang, N | 1 |
| Papastefanou, I | 1 |
| Chambers, JB | 1 |
| Cairns, AE | 1 |
| Tucker, KL | 1 |
| Leeson, P | 1 |
| Mackillop, L | 1 |
| Barton, JR | 1 |
| Tagg, WG | 1 |
| Razdan, RS | 1 |
| Swain, FR | 1 |
| Gagliardi, JA | 1 |
| Chaddha, SK | 1 |
| Yancey, LM | 1 |
| Withers, E | 1 |
| Bakes, K | 1 |
| Abbott, J | 1 |
| Carvalho, TM | 2 |
| Cavalli, Rde C | 2 |
| Marques, MP | 2 |
| Da Cunha, SP | 1 |
| Baraldi, Cde O | 1 |
| Lanchote, VL | 2 |
| Asencio Moreno, A | 1 |
| Alamán Orbañanos, B | 1 |
| Moro Velasco, MC | 1 |
| Erkinaro, T | 2 |
| Kavasmaa, T | 2 |
| Ylikauma, L | 1 |
| Mäkikallio, K | 2 |
| Haapsamo, M | 2 |
| Acharya, G | 2 |
| Ohtonen, P | 1 |
| Alahuhta, S | 1 |
| Räsänen, J | 3 |
| Shafi, NA | 1 |
| Malik, A | 1 |
| Silverman, DI | 1 |
| Keating, E | 1 |
| Gonçalves, P | 1 |
| Campos, I | 1 |
| Costa, F | 1 |
| Martel, F | 1 |
| Abdel-Hady, el-S | 1 |
| Fawzy, M | 1 |
| El-Negeri, M | 1 |
| Nezar, M | 1 |
| Ragab, A | 1 |
| Helal, AS | 1 |
| Hamaoui, A | 1 |
| Mercado, R | 1 |
| Kauntia, R | 1 |
| Valsalan, R | 1 |
| Seshadri, S | 1 |
| Pandit, VR | 1 |
| Prabhu, MM | 1 |
| Small, KR | 1 |
| Cannava, M | 1 |
| Casey, S | 1 |
| Jacques, J | 1 |
| Pasker-de Jong, PC | 1 |
| Zielhuis, GA | 1 |
| van Gelder, MM | 1 |
| Pellegrino, A | 1 |
| Gabreëls, FJ | 1 |
| Eskes, TK | 1 |
| Merino, JL | 1 |
| Espejo, B | 1 |
| Ferreiro, P | 1 |
| Bueno, B | 1 |
| Paraíso, V | 1 |
| Chan, WS | 1 |
| Barrera, M | 1 |
| Rezvani, M | 1 |
| Knittel-Keren, D | 1 |
| Nulman, I | 1 |
| Cunha, SP | 1 |
| de Baraldi, CO | 1 |
| Antunes, NJ | 1 |
| Godoy, AL | 1 |
| Santos Nores, J | 1 |
| Bravo López, JJ | 1 |
| Borrajo Prol, MP | 1 |
| Iglesias Forneiro, A | 1 |
| Baggio, MR | 1 |
| Martins, WP | 1 |
| Calderon, AC | 1 |
| Berezowski, AT | 1 |
| Marcolin, AC | 1 |
| Duarte, G | 1 |
| Cavalli, RC | 1 |
| Graham, DF | 1 |
| Hadlow, N | 1 |
| Tsokos, N | 1 |
| Oates, R | 1 |
| Yee, LM | 1 |
| Wu, D | 1 |
| Immanni, S | 1 |
| Khan, EI | 1 |
| Staunton, M | 1 |
| Kuok, CH | 1 |
| Yen, CR | 1 |
| Huang, CS | 1 |
| Ko, YP | 1 |
| Tsai, PS | 1 |
| Dueñas-Garcia, OF | 1 |
| Ciantar, E | 1 |
| Walker, JJ | 7 |
| Koucký, M | 1 |
| Baidya, DK | 1 |
| Trikha, A | 1 |
| Menon, S | 1 |
| Garg, R | 1 |
| Raheem, IA | 1 |
| Saaid, R | 1 |
| Omar, SZ | 1 |
| Tan, PC | 1 |
| Molvi, SN | 1 |
| Mir, S | 1 |
| Rana, VS | 1 |
| Jabeen, F | 1 |
| Malik, AR | 1 |
| Seal, SL | 1 |
| Ghosh, D | 1 |
| Kamilya, G | 1 |
| Mukherji, J | 1 |
| Hazra, A | 1 |
| Garain, P | 1 |
| Heida, KY | 1 |
| Zeeman, GG | 1 |
| Van Veen, TR | 1 |
| Hulzebos, CV | 1 |
| Giannubilo, SR | 1 |
| Bezzeccheri, V | 1 |
| Cecchi, S | 1 |
| Landi, B | 1 |
| Battistoni, GI | 1 |
| Vitali, P | 1 |
| Cecchi, L | 1 |
| Tranquilli, AL | 1 |
| Bennett, M | 1 |
| Daskas, N | 1 |
| Crowne, E | 1 |
| Shield, JP | 1 |
| Liu, QQ | 1 |
| Yu, YH | 1 |
| Gong, SP | 1 |
| Huang, LP | 1 |
| McGuinness, N | 1 |
| Cording, V | 1 |
| Verhagen, EA | 1 |
| van den Berg, PP | 1 |
| Newbould, S | 1 |
| Elatrous, S | 1 |
| Nouira, S | 1 |
| Ouanes Besbes, L | 1 |
| Marghli, S | 1 |
| Boussarssar, M | 1 |
| Sakkouhi, M | 1 |
| Abroug, F | 1 |
| Tooke-Miller, C | 1 |
| Allen, JC | 1 |
| Dizon-Townson, D | 1 |
| Varner, MA | 1 |
| Skoczyński, M | 1 |
| Semczuk, M | 1 |
| Mok, CC | 1 |
| Kwan, TH | 1 |
| Chow, L | 1 |
| De Conti, F | 1 |
| Da Cortà, R | 1 |
| Del Monte, D | 1 |
| Catena, V | 1 |
| Berton, G | 1 |
| Mormino, P | 1 |
| Pecoraro, L | 1 |
| Piovesana, P | 1 |
| Reyes, M | 1 |
| Pan, PH | 1 |
| Houlihan, DD | 1 |
| Dennedy, MC | 1 |
| Ravikumar, N | 1 |
| Morrison, JJ | 1 |
| Mansour, G | 1 |
| Mansour, J | 1 |
| Fynn, J | 1 |
| Venyo, AK | 1 |
| Stählin, P | 1 |
| Gremmelmaier, D | 1 |
| Murphy, MA | 1 |
| Ayazifar, M | 1 |
| Patel, N | 1 |
| Riordan-Eva, P | 1 |
| Chong, V | 1 |
| Balestrieri, PJ | 1 |
| Hamza, MS | 1 |
| Ting, PH | 1 |
| Blank, RS | 1 |
| Grubb, CT | 1 |
| Heazell, AE | 1 |
| Mahomoud, S | 1 |
| Pirie, AM | 1 |
| Neri, I | 1 |
| Jasonni, VM | 1 |
| Gori, GF | 1 |
| Blasi, I | 1 |
| Facchinetti, F | 1 |
| Sibai, B | 2 |
| Frishman, WH | 1 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Chan, S | 1 |
| Hewson, S | 1 |
| Kavuma, E | 1 |
| McKay, D | 1 |
| Ohlsson, A | 1 |
| Willan, AR | 1 |
| Hannah, ME | 1 |
| Hatfield, T | 1 |
| Steiger, R | 1 |
| Wing, DA | 1 |
| Omu, AE | 2 |
| Al-Harmi, J | 1 |
| Vedi, HL | 1 |
| Mlechkova, L | 1 |
| Sayed, AF | 1 |
| Al-Ragum, NS | 1 |
| Erwin, L | 1 |
| Lang, G | 1 |
| Prentice, CR | 2 |
| Belch, JJ | 2 |
| McLaren, M | 2 |
| Forbes, CD | 4 |
| Calder, AA | 7 |
| Smith, AM | 1 |
| Walker, H | 1 |
| Bonduelle, M | 1 |
| Greer, I | 2 |
| Lardoux, H | 6 |
| Gerard, J | 6 |
| Blazquez, G | 6 |
| Flouvat, B | 3 |
| Lubbe, WF | 1 |
| Lund-Johansen, P | 1 |
| Louis, WJ | 1 |
| McNeil, JJ | 1 |
| Drummer, OH | 1 |
| Prichard, BN | 2 |
| Mounac, M | 1 |
| Giraud, P | 1 |
| Jeuffroy, A | 1 |
| Riley, AJ | 1 |
| Broughton Pipkin, F | 5 |
| Symonds, EM | 4 |
| Lamming, GD | 3 |
| Jadoul, FA | 1 |
| Millar, JA | 1 |
| Wilson, PD | 1 |
| Morrison, N | 1 |
| Hammerle, AF | 1 |
| Ram, CV | 2 |
| Greer, IA | 2 |
| Dubois, D | 1 |
| Petitcolas, J | 1 |
| Temperville, B | 1 |
| Klepper, A | 1 |
| Leboullenger, P | 1 |
| Nylund, L | 4 |
| Lunell, NO | 7 |
| Lewander, R | 4 |
| Sarby, B | 3 |
| Thornström, S | 2 |
| Mamoun, I | 1 |
| Sarby, S | 1 |
| Galletly, DC | 1 |
| Yee, P | 1 |
| Maling, TJ | 1 |
| Woods, DL | 1 |
| Malan, AF | 1 |
| Chouty, F | 2 |
| Beauséjour, B | 1 |
| Faurie, C | 1 |
| Rousset, D | 1 |
| Lang, GD | 1 |
| Lowe, GD | 1 |
| Rubin, PC | 1 |
| Butters, L | 1 |
| Kelman, AW | 1 |
| Fitzsimons, C | 1 |
| Reid, JL | 1 |
| Fredholm, B | 1 |
| Hjemdahl, P | 2 |
| Nisell, H | 2 |
| Persson, B | 2 |
| Wager, J | 2 |
| Michael, CA | 4 |
| Robertson, JI | 1 |
| Garden, A | 1 |
| Davey, DA | 1 |
| Dommisse, J | 1 |
| Fredholm, BB | 1 |
| Whalley, ET | 3 |
| Stevens, TP | 1 |
| Guillet, R | 1 |
| el-Qarmalawi, AM | 1 |
| Morsy, AH | 1 |
| al-Fadly, A | 1 |
| Obeid, A | 1 |
| Hashem, M | 1 |
| de Vries, TW | 1 |
| van der Veer, E | 1 |
| Heijmans, HS | 1 |
| Verkeste, CM | 1 |
| Peeters, LL | 1 |
| Connelly, JF | 1 |
| Petersen, OB | 1 |
| Skajaa, K | 2 |
| Svane, D | 1 |
| Gregersen, H | 1 |
| Forman, A | 2 |
| Spassov, L | 1 |
| Curzi-Dascalova, L | 1 |
| Clairambault, J | 1 |
| Kauffmann, F | 1 |
| Eiselt, M | 1 |
| Médigue, C | 1 |
| Peirano, P | 1 |
| Tin, LN | 1 |
| Mulard, C | 1 |
| Talon, A | 1 |
| Garnier, JM | 1 |
| Lambert, A | 1 |
| Stroch-Marcy, A | 1 |
| Kamara, S | 1 |
| Kantola, I | 1 |
| Kaila, T | 1 |
| Erkkola, R | 1 |
| Jouppila, P | 2 |
| Klarr, JM | 1 |
| Bhatt-Mehta, V | 1 |
| Donn, SM | 1 |
| Saotome, T | 1 |
| Minoura, S | 1 |
| Terashi, K | 1 |
| Sato, T | 1 |
| Echizen, H | 1 |
| Ishizaki, T | 1 |
| Yeleswaram, K | 3 |
| Rurak, DW | 4 |
| Kwan, E | 1 |
| Hall, C | 3 |
| Doroudian, A | 2 |
| Wright, MR | 2 |
| Abbott, FS | 2 |
| Axelson, JE | 4 |
| Hjertberg, R | 2 |
| Faxelius, G | 2 |
| Belfrage, P | 1 |
| Mahmoud, TZ | 1 |
| Bjornsson, S | 1 |
| Bhorat, IE | 1 |
| Naidoo, DP | 1 |
| Rout, CC | 1 |
| Moodley, J | 2 |
| Lagercrantz, H | 1 |
| Morgan, MA | 1 |
| Silavin, SL | 1 |
| Dormer, KJ | 1 |
| Fishburne, BC | 1 |
| Fishburne, JI | 1 |
| Hurst, JA | 1 |
| Houlston, RS | 1 |
| Roberts, A | 1 |
| Gould, SJ | 1 |
| Tingey, WG | 1 |
| Tonn, GR | 1 |
| Gordon, JG | 1 |
| Riggs, KW | 1 |
| Orpana, AK | 1 |
| Avela, K | 1 |
| Ranta, V | 1 |
| Viinikka, L | 2 |
| Ylikorkala, O | 3 |
| Sakamoto, H | 1 |
| Misumi, K | 1 |
| Matsuda, Y | 1 |
| Ikenoue, T | 1 |
| Santeiro, ML | 1 |
| Stromquist, C | 1 |
| Wyble, L | 1 |
| Makhseed, M | 1 |
| al-Qattan, F | 1 |
| Chu, YL | 1 |
| Lin, SY | 1 |
| Lee, PC | 1 |
| Wang, YP | 1 |
| Lee, LH | 1 |
| Liu, CC | 1 |
| Gazzolo, D | 1 |
| Visser, GH | 1 |
| Russo, A | 1 |
| Scopesi, F | 1 |
| Santi, F | 1 |
| Bruschettini, PL | 1 |
| Kirsten, R | 1 |
| Nelson, K | 1 |
| Kirsten, D | 1 |
| Heintz, B | 1 |
| Bowman, ML | 1 |
| Bergmann, M | 1 |
| Smith, JF | 1 |
| Crooks, BN | 1 |
| Deshpande, SA | 1 |
| Platt, MP | 1 |
| Milligan, DW | 1 |
| Ramanathan, J | 2 |
| Angel, JJ | 1 |
| Bush, AJ | 1 |
| Lawson, P | 1 |
| Vyas, S | 1 |
| Kumar, A | 1 |
| Piecuch, S | 1 |
| Hidalgo, G | 1 |
| Singh, A | 1 |
| Anderson, V | 1 |
| Markell, MS | 1 |
| Baqi, N | 1 |
| Boulton, DW | 1 |
| Dakers, JM | 1 |
| Fawcett, JP | 1 |
| Fiddes, TM | 1 |
| Midgley, DY | 1 |
| Khalaf, Y | 1 |
| Braude, PR | 1 |
| Vermillion, ST | 2 |
| Scardo, JA | 2 |
| Newman, RB | 2 |
| Chauhan, SP | 2 |
| Hogg, BB | 1 |
| Varon, J | 1 |
| Marik, PE | 1 |
| Pittman, JA | 1 |
| Bull, SB | 1 |
| Logan, A | 1 |
| Ito, A | 1 |
| Shimano, Y | 1 |
| Otsuka, Y | 1 |
| Kato, M | 1 |
| Usami, T | 1 |
| Takeuchi, O | 1 |
| Koyama, K | 1 |
| Morozumi, K | 1 |
| Sano, T | 1 |
| Fukazu, A | 1 |
| Kimura, G | 1 |
| Laml, T | 1 |
| Hartmann, BW | 1 |
| Preyer, O | 1 |
| Ruecklinger, E | 1 |
| Soeregi, G | 1 |
| Wagenbichler, P | 1 |
| Bolte, AC | 1 |
| van Geijn, HP | 1 |
| Dekker, GA | 1 |
| Hussein, M | 1 |
| Mooij, JM | 1 |
| Roujouleh, H | 1 |
| Rollins, G | 1 |
| Rosenthal, T | 1 |
| Oparil, S | 1 |
| Carey, B | 1 |
| Symonds, EB | 1 |
| Richards, DA | 1 |
| Martin, LE | 3 |
| Hopkins, R | 2 |
| Bland, R | 2 |
| Poynter, D | 1 |
| Harrison, C | 1 |
| Cook, J | 1 |
| Joekes, AM | 1 |
| Thompson, FD | 1 |
| Munshi, UK | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Singh, M | 1 |
| Olsen, KS | 2 |
| Beier-Holgersen, R | 2 |
| Pickles, CJ | 2 |
| Leloux, MS | 1 |
| Jongsma, HW | 1 |
| Cruickshank, DJ | 2 |
| Robertson, AA | 1 |
| Campbell, DM | 2 |
| MacGillivray, I | 1 |
| Eisenach, JC | 1 |
| Mandell, G | 1 |
| Dewan, DM | 1 |
| Shen, JJ | 1 |
| Wanwimolruk, S | 1 |
| Mills, RG | 1 |
| Roberts, MS | 1 |
| Pirhonen, JP | 2 |
| Erkkola, RU | 2 |
| Mäkinen, JI | 2 |
| Ekblad, UU | 2 |
| Fairlie, FM | 2 |
| Verdile, VP | 1 |
| Verdile, LA | 1 |
| Allen, J | 1 |
| Maigaard, S | 1 |
| Harper, A | 1 |
| Murnaghan, GA | 1 |
| Mabie, WC | 5 |
| Shamsa, F | 1 |
| Villar, MA | 1 |
| Anderson, GD | 2 |
| Chrisp, P | 1 |
| Goa, KL | 1 |
| Rogers, RC | 1 |
| Whybrew, WD | 1 |
| Haraldsson, A | 2 |
| Geven, W | 2 |
| Lavies, NG | 1 |
| Meiklejohn, BH | 1 |
| May, AE | 1 |
| Achola, KJ | 1 |
| Fell, D | 1 |
| Chimura, T | 1 |
| Naden, RP | 1 |
| Redman, CW | 1 |
| Kanto, JH | 1 |
| Durando, C | 1 |
| Leidi, L | 1 |
| Margaria, E | 1 |
| Medaglia, M | 1 |
| Gessa, M | 1 |
| Maina, G | 1 |
| Thulesius, O | 1 |
| Ibrahim, M | 1 |
| Moberger, B | 1 |
| Angilivilayil, C | 1 |
| Schneider, H | 1 |
| Proegler, M | 1 |
| Ahokas, RA | 1 |
| Leperlier, E | 2 |
| Acciaro, E | 1 |
| Acciaro, L | 1 |
| La Scala, G | 1 |
| Giuseppini, S | 1 |
| Valentini, A | 1 |
| Plouin, PF | 2 |
| Breart, G | 2 |
| Maillard, F | 2 |
| Papiernik, E | 2 |
| Relier, JP | 2 |
| Gonzalez, AR | 2 |
| Amon, E | 1 |
| Elkington, KW | 1 |
| Chauhan, D | 1 |
| Ruiz, AG | 1 |
| Kirkinen, P | 1 |
| Koivula, A | 1 |
| Ashe, RG | 1 |
| Richards, AM | 1 |
| Philpott, RH | 1 |
| Rasmussen, K | 1 |
| Moretti, M | 1 |
| Macpherson, M | 1 |
| Rutter, N | 1 |
| Meese, RB | 1 |
| Kulas, J | 1 |
| Rane, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The CHIPS Trial (Control of Hypertension In Pregnancy Study)[NCT01192412] | 987 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Early Vascular Adjustments to Prevent Preeclampsia and Related Complications[NCT04216706] | 314 participants (Actual) | Observational | 2014-11-01 | Completed | |||
| A Randomized Control Trial of Furosemide or Placebo With Usual Antihypertensives in the Antepartum Management of Severe Hypertension With Wide Pulse Pressure[NCT04615624] | Phase 3 | 65 participants (Actual) | Interventional | 2021-01-04 | Completed | ||
| Use of Meditation as a Complementary Therapy in the Treatment of Gestational Hypertension[NCT03873194] | 47 participants (Actual) | Interventional | 2019-04-15 | Completed | |||
| Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy[NCT01912677] | Phase 4 | 894 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial[NCT03262961] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-15 | Recruiting | ||
| The Effect of Prophylactic Magnesium Use in Pregnant Women on Reversal of Neuromuscular Block With Sugammadex:Evaluation With TOF[NCT05558969] | 30 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | |||
| Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)[NCT03269110] | 2,578 participants (Anticipated) | Observational | 2017-07-01 | Enrolling by invitation | |||
| Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET)[NCT00293735] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to Lack of funding) | ||
| Effectiveness of Subarachnoid Hyperbaric Bupivacaine on Mean Arterial Blood Pressure in Pregnant Patients With Obesity Operated by Cesarean Section[NCT04205344] | Phase 4 | 40 participants (Actual) | Interventional | 2017-02-01 | Completed | ||
| Effect of Subarachnoid Hyperbaric Bupivacaine on Mean Arterial Pressure in Obese Pregnant Patients Undergoing Cesarean Section[NCT06060015] | Phase 4 | 106 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pregnancy loss or NICU admission for greater than 48 hours, as recorded in the maternal and infant medical records immediately following the birth (or pregnancy loss), and then again after the mothers' and infants' discharge home. Supplemental information, about potential post-discharge maternal or neonatal morbidities in the 6 weeks following birth for the mother, or 28 days of life for the baby, will be obtained by contacting women at 6 weeks postpartum and/or from medical records. (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 155 |
| 'Tight' Control. | 150 |
"Serious maternal complications measured up to 6 weeks postpartum. Death or one or more life-threatening maternal complications:~Adverse neurological complications (stroke, eclampsia, and/or blindness), and/or~End-organ failure (uncontrolled hypertension, inotropic support, pulmonary oedema, respiratory failure, myocardial ischaemia/infarction, renal failure, coagulopathy, and/or transfusion)" (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 18 |
| 'Tight' Control. | 10 |
54 reviews available for labetalol and Pregnancy
| Article | Year |
|---|---|
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pha | 2021 |
Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Patient | 2022 |
Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Hypertension, Pr | 2022 |
Hypertensive Disorders of Pregnancy: Common Clinical Conundrums.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; P | 2022 |
Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; M | 2022 |
Hypertensive Crisis in Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Labetalol; Nifedipine; Pregnancy | 2022 |
Cardiac medications in obstetric patients.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Female; Hematologic Agents; Humans; Hyperte | 2023 |
Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis.
Topics: Blood Pressure; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pregnancy | 2023 |
Evaluation and Management of Hypertensive Disorders of Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Labetalol | 2023 |
Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retarda | 2020 |
Postpartum Hypertension: Etiology, Diagnosis, and Management.
Topics: Antihypertensive Agents; Blood Pressure; Disease Management; Female; Humans; Hydralazine; Hypertensi | 2017 |
In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review.
Topics: Antihypertensive Agents; Attention Deficit Disorder with Hyperactivity; Birth Weight; Child; Child H | 2017 |
Pathophysiology and Current Clinical Management of Preeclampsia.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delivery, Obstetric; Endothelium, | 2017 |
New Evidence in the Management of Chronic Hypertension in Pregnancy.
Topics: Algorithms; Antihypertensive Agents; Blood Pressure; Chronic Disease; Female; Humans; Hypertension; | 2017 |
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Headache; Humans; Hydralazine; Hy | 2018 |
What is the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy?
Topics: Antihypertensive Agents; Evidence-Based Medicine; Female; Humans; Hypertension, Pregnancy-Induced; L | 2018 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Hypertensive emergencies of pregnancy.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Creatine; Diuretics; Emergency Medicine; Female; | 2013 |
Severe pre-eclampsia and hypertensive crises.
Topics: Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Critical Care; Early Dia | 2013 |
The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypotension; Infant, Newborn; Labetalol; Nica | 2014 |
Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.
Topics: Administration, Oral; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension, Pregnancy- | 2014 |
Hypertensive emergencies in pregnancy.
Topics: Antihypertensive Agents; Eclampsia; Emergencies; Female; Humans; Hydralazine; Hypertension; Hyperten | 2014 |
Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy.
Topics: Administration, Oral; Antihypertensive Agents; Female; Humans; Hypertension; Infusions, Intravenous; | 2015 |
Labetalol for hypertension in pregnancy.
Topics: Antihypertensive Agents; Canada; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Practic | 2015 |
Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Cost-Benefit Anal | 2016 |
A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, | 2015 |
Hypertensive Emergencies in Pregnancy.
Topics: Antihypertensive Agents; Cesarean Section; Chronic Disease; Congenital Abnormalities; Emergencies; E | 2016 |
Posterior reversible encephalopathy syndrome following a cesarean delivery: case report and literature review.
Topics: Adult; Anticonvulsants; Antihypertensive Agents; Cesarean Section; Eclampsia; Female; Humans; Hypert | 2008 |
Pre-eclampsia, severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelets syndrome: what is new?
Topics: Anticoagulants; Antihypertensive Agents; Female; HELLP Syndrome; Heparin; Humans; Hypertension, Preg | 2011 |
[Current perspective of treating hypertension in pregnancy].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hypertension; Hypertension, Pregn | 2011 |
[Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis].
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Infant, Newborn; | 2012 |
Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate.
Topics: Anticonvulsants; Antihypertensive Agents; Cerebrovascular Circulation; Eclampsia; Female; Humans; La | 2006 |
Pathophysiology and medical management of systemic hypertension in preeclampsia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium; Calcium Channel Blockers; Cerebral Hemorrhage; Female | 2006 |
Goodpasture's disease in pregnancy: case report and review of the literature.
Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antihypertensive Agents; Female; Humans; Hypertens | 2007 |
Hypertension in pregnancy. Pathophysiology and management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Clon | 1984 |
Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Cerebro | 1984 |
Pharmacology of combined alpha-beta-blockade. I.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Biological Availability; Chemica | 1984 |
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
Clinical pharmacology of labetalol in pregnancy.
Topics: Ethanolamines; Female; Fetus; Heart Rate; Humans; Hypertension; Infant, Newborn; Kidney; Labetalol; | 1981 |
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
Antihypertensive drugs of choice for treating preeclampsia.
Topics: Antihypertensive Agents; Female; Fetal Distress; Humans; Labetalol; Nifedipine; Pre-Eclampsia; Pregn | 1994 |
New approaches for drug and kinetic analysis in the maternal-fetal unit.
Topics: Animals; Diphenhydramine; Female; Fetus; Labetalol; Metoclopramide; Pregnancy; Pregnancy, Animal; Sh | 1995 |
Clinical pharmacokinetics of vasodilators. Part II.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Alprostadil; Amrinone; Carbazoles; Carvedilo | 1998 |
The diagnosis and management of hypertensive crises.
Topics: Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Clonidine; Diazoxide; Enalaprilat; Fema | 2000 |
The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy.
Topics: Adrenergic beta-Antagonists; Adult; Cohort Studies; Databases as Topic; Diabetes, Gestational; Femal | 2001 |
Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diureti | 2001 |
The effect of antihypertensive drugs on the fetus.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; An | 2002 |
Doppler flow velocimetry in hypertension in pregnancy.
Topics: Female; Fetus; Hemodynamics; Humans; Hypertension; Labetalol; Mass Screening; Nifedipine; Placenta; | 1991 |
Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
Topics: Animals; Dogs; Female; Guinea Pigs; Humans; Hypertension; Labetalol; Pregnancy; Randomized Controlle | 1990 |
Antihypertensive drugs in pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diazoxide; Diuretics; Female; Fetus; Humans; H | 1985 |
Current status of labetalol, the first alpha- and beta-blocking agent.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Biot | 1985 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
60 trials available for labetalol and Pregnancy
| Article | Year |
|---|---|
Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Infant; Infant, | 2022 |
Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension.
Topics: Antihypertensive Agents; Blood Coagulation; Blood Pressure; Female; Humans; Hypertension; Hypertensi | 2022 |
Labetalol, Low-dose Aspirin, and Vitamin E and Calcium for Gestational Hypertension and Influence on MicroRNA-126 and PLGF Levels.
Topics: Aspirin; Calcium; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; MicroRNA | 2023 |
Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Female; Hemodynamics; Humans; Infusions, Intraveno | 2023 |
Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.
Topics: Antihypertensive Agents; Female; Humans; Hydralazine; Labetalol; Nifedipine; Pre-Eclampsia; Pregnanc | 2022 |
A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA).
Topics: Animals; Antihypertensive Agents; Female; Humans; Hypertension; Infant; Infant, Newborn; Labetalol; | 2023 |
Quantifying adherence to antihypertensive medication for chronic hypertension during pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Chromatography, High Pressure Liquid; | 2019 |
Management of non-severe pregnancy hypertension - A summary of the CHIPS Trial (Control of Hypertension in Pregnancy Study) research publications.
Topics: Adult; Antihypertensive Agents; Canada; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; | 2019 |
Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension; Hypertension, Pregnancy- | 2020 |
Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Cerebrovascular Circulation; Cohort Studies; F | 2020 |
To study the changes in maternal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; F | 2020 |
Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Methyldopa; | 2020 |
Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Do | 2020 |
Lipid profile and cytokines in hypertension of pregnancy: A comparison of preeclampsia therapies.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cytokines; Double-Blind Method; Drug Administration | 2018 |
Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study.
Topics: Adult; Antihypertensive Agents; Birth Weight; Black People; Blood Pressure; Chronic Disease; Cohort | 2019 |
Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy.
Topics: Adrenergic beta-Antagonists; Adult; Case-Control Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 | 2018 |
To study the changes in fetal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; F | 2019 |
IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Double-Blind Method; Fem | 2019 |
Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, | 2019 |
Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; D | 2013 |
Fetomaternal outcome in severe preeclamptic women undergoing emergency cesarean section under either general or spinal anesthesia.
Topics: Adolescent; Adult; Anesthesia, General; Anesthesia, Spinal; Anticonvulsants; Antihypertensive Agents | 2014 |
Impedance cardiography assessed treatment of acute severe pregnancy hypertension: a randomized trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiac Output; Cardiography, Impedance; Female; Hum | 2016 |
Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Decision-Making; Female; Humans; Hypertensi | 2016 |
Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnanc | 2016 |
Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; D | 2016 |
Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Area Under Curve; Blood Pressure; Diabetes | 2011 |
Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial.
Topics: Acute Disease; Adult; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Labetalol; | 2011 |
Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Emergenci | 2012 |
Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Humans; Hypertension, Pregnancy-Induced; I | 2012 |
Does route of delivery affect maternal and perinatal outcome in women with eclampsia? A randomized controlled pilot study.
Topics: Adult; Anticonvulsants; Antihypertensive Agents; Apgar Score; Cesarean Section; Critical Care; Eclam | 2012 |
Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nicardipine; Pre-Eclampsia; | 2002 |
Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial.
Topics: Adolescent; Adult; Antihypertensive Agents; Arginine; Blood Pressure; Female; Gestational Age; Human | 2006 |
The Control of Hypertension In Pregnancy Study pilot trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Patient Sat | 2007 |
Labetalol and platelet function in pre-eclampsia.
Topics: Blood Platelets; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypertension; Labetalol; P | 1982 |
Antihypertensive therapy in pregnancy.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Labetalol; Ma | 1983 |
Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared.
Topics: Ethanolamines; Female; Heart Rate; Humans; Hydralazine; Hypertension; Labetalol; Pregnancy; Pregnanc | 1983 |
Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy.
Topics: Adult; Blood Pressure; Dihydralazine; Eclampsia; Ethanolamines; Female; Fetus; Humans; Hydralazine; | 1982 |
Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Creatinine; Ethanolamines; Female; Fetus; Humans; Hydralazine; Hypertension; | 1980 |
Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants.
Topics: Adult; Female; Humans; Hydralazine; Infant, Low Birth Weight; Infant, Newborn; Labetalol; Pre-Eclamp | 1993 |
Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine.
Topics: Adolescent; Adult; Dihydralazine; Eclampsia; Electrocardiography, Ambulatory; Female; Humans; Infusi | 1993 |
Effect of antihypertensive therapy in preeclampsia on levels of serum interleukin-4.
Topics: Adult; Antihypertensive Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydralazine; Infu | 1996 |
A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; | 1999 |
A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; E | 1999 |
Use of labetalol and methyldopa in pregnancy-induced hypertension.
Topics: Administration, Oral; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Injections, Intra | 1979 |
A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension.
Topics: Administration, Oral; Adult; Female; Gestational Age; Humans; Hypertension; Labetalol; Length of Sta | 1992 |
Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study.
Topics: Adult; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Complications; Pregnancy Compli | 1992 |
Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Female; Heart Rate; Heart Rate, Fetal; Hemodynamics; Hum | 1991 |
A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy.
Topics: Adult; Female; Humans; Hypertension; Infant Mortality; Infant, Newborn; Labetalol; Methyldopa; Pregn | 1990 |
Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
Topics: Animals; Dogs; Female; Guinea Pigs; Humans; Hypertension; Labetalol; Pregnancy; Randomized Controlle | 1990 |
Atenolol in essential hypertension during pregnancy.
Topics: Atenolol; Female; Fetal Growth Retardation; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Co | 1990 |
The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Infant, Newborn; | 1989 |
Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial.
Topics: Adult; Clinical Trials as Topic; Female; Fetal Death; Fetus; Hemodynamics; Humans; Hypertension; Inf | 1988 |
[Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial].
Topics: Adult; Clinical Trials as Topic; Female; Humans; Hypertension; Labetalol; Methyldopa; Pregnancy; Pre | 1987 |
[Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol].
Topics: Acebutolol; Adult; Female; Heart Rate, Fetal; Humans; Hypertension; Hypoglycemia; Infant, Newborn; L | 1988 |
A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; H | 1987 |
The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia.
Topics: Adolescent; Adult; Anesthesia, Obstetrical; Blood Pressure; Cesarean Section; Female; Humans; Hypert | 1988 |
Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy.
Topics: Adolescent; Adult; Birth Weight; Clinical Trials as Topic; Delivery, Obstetric; Diazoxide; Female; H | 1986 |
Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy.
Topics: Blood Pressure; Clinical Trials as Topic; Dihydralazine; Female; Heart Rate; Heart Rate, Fetal; Huma | 1987 |
A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term.
Topics: Adult; Blood Pressure; Female; Fetal Growth Retardation; Hospitalization; Humans; Labetalol; Pre-Ecl | 1987 |
201 other studies available for labetalol and Pregnancy
| Article | Year |
|---|---|
Severe hypertension in pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Pre-Eclampsia; Pre | 2021 |
Which antihypertensive treatment is better for mild to moderate hypertension in pregnancy?
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Methyldopa; Nif | 2022 |
Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study.
Topics: Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension, Pregnancy-Induced; Infant; Infa | 2022 |
Uterine Ultrasound Doppler Hemodynamics of Magnesium Sulfate Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension Using Empirical Wavelet Transform Algorithm.
Topics: Algorithms; Female; Hemodynamics; Humans; Hypertension, Pregnancy-Induced; Labetalol; Magnesium Sulf | 2022 |
In Vitro Toxicological Profile of Labetalol-Folic Acid/Folate Co-Administration in H9c2(2-1) and HepaRG Cells.
Topics: Dietary Supplements; Female; Folic Acid; Humans; Hypertension; Labetalol; Neural Tube Defects; Pregn | 2022 |
Race/ethnicity differences in response to acute antihypertensive treatment of peripartum severe hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Ethnicity; Female; Humans; Hydralazine; Hypertension; Labet | 2022 |
Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine.
Topics: Antihypertensive Agents; Cohort Studies; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2022 |
Hypertensive Conditions: Hypertensive Disorders in Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pre | 2022 |
Use of continuous infusion of nicardipine to control persistent postpartum hypertension: A retrospective study.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Labetalol; Nicar | 2022 |
Identifying Targets to Improve the Management of Severe Hypertension in Pregnancy and Postpartum.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Physiologically Based Pharmacokinetic Modeling for Multiple Oral Administration Labetalol in Pregnant Women.
Topics: Administration, Oral; Blood Pressure; Cytochrome P-450 CYP2C19; Female; Humans; Labetalol; Pregnancy | 2023 |
Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Hypotension; Lab | 2023 |
Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia.
Topics: Antihypertensive Agents; Blood Pressure; East Asian People; Female; Humans; Hypertension; Infant, Ne | 2023 |
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Topics: Administration, Oral; Adult; E-Selectin; Female; Humans; Labetalol; Magnesium Sulfate; Nifedipine; P | 2020 |
Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women.
Topics: Administration, Intravenous; Adult; Antihypertensive Agents; Apgar Score; Asian People; Blood Pressu | 2020 |
Coarctation of the aorta: a rare cause of severe hypertension in pregnancy.
Topics: Adolescent; Antihypertensive Agents; Aortic Coarctation; Computed Tomography Angiography; Electrocar | 2020 |
[THE EFFECT OF MAGNESIUM SULPHATE AND LABETALOL ON PLACENTAL VESSELS REACTIVITY USING THE EX-VIVO PLACENTAL PERFUSION MODEL].
Topics: Female; Fetus; Humans; Labetalol; Magnesium Sulfate; Placenta; Pre-Eclampsia; Pregnancy | 2020 |
Semiautonomous Treatment Algorithm for the Management of Severe Hypertension in Pregnancy.
Topics: Adult; Algorithms; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetal | 2021 |
Pharmacological strategies to prevent haemodynamic changes after intubation in parturient women with hypertensive disorders of pregnancy: A network meta-analysis.
Topics: Anesthesia, General; Antihypertensive Agents; Apgar Score; Blood Pressure; Blood Pressure Determinat | 2021 |
Comparison of the effects on maternal endothelial cell activation: an in vitro study of anti-hypertensive drugs clinically used in pre-eclampsia.
Topics: Antihypertensive Agents; Endothelial Cells; Female; Humans; Labetalol; Placenta; Pre-Eclampsia; Preg | 2022 |
Preventing Recurrent Preeclampsia by Tailored Treatment of Nonphysiologic Hemodynamic Adjustments to Pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Hemodynamics; Humans; Labetalol; Methyldopa; | 2021 |
Pulse pressure as a predictor of response to treatment for severe hypertension in pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, Pregnancy-Induced; Infant; La | 2021 |
Committee Opinion No. 692 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Administration Routes; E | 2017 |
Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Administration Routes; E | 2017 |
A case of paradoxical presentation of a postural postdural puncture headache after combined spinal-epidural anesthesia.
Topics: Acetaminophen; Adult; Analgesics, Opioid; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, | 2017 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Treating normal early gestation placentae with preeclamptic sera produces extracellular micro and nano vesicles that activate endothelial cells.
Topics: Cells, Cultured; Endothelial Cells; Extracellular Vesicles; Female; HMGB1 Protein; Humans; Immune Se | 2017 |
A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Administratio | 2017 |
Clinical and radiological features of posterior reversible encephalopathy syndrome in patients with pre-eclampsia and eclampsia.
Topics: Adult; Anticonvulsants; Antihypertensive Agents; Brain; Diazepam; Eclampsia; Female; Humans; Labetal | 2017 |
Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension.
Topics: Antihypertensive Agents; Bangladesh; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pre | 2017 |
Pregnancy-associated spontaneous coronary artery dissection (PASCAD): An etiology for chest pain in the young peripartum patient.
Topics: Adult; Antihypertensive Agents; Aortic Dissection; Chest Pain; Coronary Aneurysm; Electrocardiograph | 2018 |
The effect of labetalol and nifedipine MR on blood pressure in women with chronic hypertension in pregnancy.
Topics: Adrenergic Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chronic D | 2018 |
Inadvertent epidural injection of labetalol during labor.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthesiologists; Anesthetics, Local; Female; H | 2018 |
Use of Antihypertensive Medications and Uterotonics During Delivery Hospitalizations in Women With Asthma.
Topics: Adult; Antihypertensive Agents; Asthma; Carboprost; Contraindications, Drug; Databases, Factual; Del | 2018 |
Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms.
Topics: Algorithms; Antihypertensive Agents; Delivery Rooms; Delivery, Obstetric; Female; Guideline Adherenc | 2018 |
Beta-blocker subtypes and risk of low birth weight in newborns.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Birth Weight; California; Fem | 2018 |
Posterior reversible encephalopathy syndrome, preeclampsia or stroke? A diagnostic dilemma.
Topics: Abdominal Pain; Adrenergic beta-Antagonists; Aspirin; Diagnosis, Differential; Factor V; Female; Hea | 2019 |
Oral regimen management of acute hypertension in pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Methyldopa; Nifedipine; Pregnancy; | 2019 |
Effect of maternal use of labetalol on the cerebral autoregulation in premature infants.
Topics: Arterial Pressure; Blood Pressure; Cerebrum; Female; Gestational Age; Homeostasis; Humans; Hypotensi | 2013 |
Outpatient calcium-channel blockers and the risk of postpartum haemorrhage: a cohort study.
Topics: Adolescent; Adult; Antihypertensive Agents; Calcium Channel Blockers; Cohort Studies; Female; Humans | 2013 |
Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Hypertens | 2013 |
Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.
Topics: Adolescent; Adult; Antihypertensive Agents; Body Weight; Dose-Response Relationship, Drug; Female; G | 2014 |
[Electrolyte disorders in preeclampsia. A case report].
Topics: Adult; Aldosterone; Antihypertensive Agents; Capillary Leak Syndrome; Cesarean Section; Emergencies; | 2014 |
Association between labetalol use for hypertension in pregnancy and adverse infant outcomes.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; In | 2014 |
Bilateral retinal detachment: a clue to diagnosis of HELLP syndrome.
Topics: Administration, Oral; Anticonvulsants; Antihypertensive Agents; Betamethasone; Drug Combinations; Fe | 2014 |
Influence of the maternal use of labetalol on the neurogenic mechanism for cerebral autoregulation assessed by means of NIRS.
Topics: Antihypertensive Agents; Brain; Female; Humans; Infant, Newborn; Labetalol; Maternal Exposure; Pregn | 2014 |
[Toxic hepatocellular hepatitis due to labetalol].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Asymptomatic Diseases; Chemical and Drug Induced Liv | 2015 |
In-vitro study of the effect of anti-hypertensive drugs on placental hormones and angiogenic proteins synthesis in pre-eclampsia.
Topics: Activins; Angiogenic Proteins; Antigens, CD; Antihypertensive Agents; Chorionic Gonadotropin; Chorio | 2014 |
A case of probable labetalol induced hyperkalaemia in pre-eclampsia.
Topics: Antihypertensive Agents; Female; Humans; Hyperkalemia; Labetalol; Pre-Eclampsia; Pregnancy; Young Ad | 2014 |
Labetalol for hypertension during pregnancy and nipple pain.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nipples; Pain; Pregnancy; P | 2014 |
First case report of acute generalized exanthematous pustulosis due to labetalol.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenergic Antagonists; Adult; Antihypertensive Agents; | 2015 |
Oral nifedipine or intravenous labetalol for severe hypertension?
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pra | 2016 |
The benefits/risks of treatment of non-severe hypertension in pregnancy and choice of drug remain unanswered.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Methyldopa; Pregnancy; Risk Assess | 2016 |
Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Follow-Up Studies; Humans; Hypertension; L | 2015 |
Severe maternal morbidity in a large cohort of women with acute severe intrapartum hypertension.
Topics: Adult; Antihypertensive Agents; California; Female; Humans; Hydralazine; Hypertension, Pregnancy-Ind | 2016 |
Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension, Pregnancy | 2016 |
The Effect of Maternal Antihypertensive Drugs on the Cerebral, Renal and Splanchnic Tissue Oxygen Extraction of Preterm Neonates.
Topics: Antihypertensive Agents; Brain; Cerebrovascular Circulation; Female; Gestational Age; Hemodynamics; | 2016 |
Isolated oculomotor nerve palsy with complete recovery in eclampsia: A rare presentation.
Topics: Adult; Anticonvulsants; Antihypertensive Agents; Brain; Diagnostic Techniques, Ophthalmological; Ecl | 2016 |
Neonatal haemodynamic effects following foetal exposure to labetalol in hypertensive disorders of pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Case-Control Studies; Cerebrum; Female; Gestational Age; He | 2017 |
A prediction model for the response to oral labetalol for the treatment of antenatal hypertension.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Logistic | 2017 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Longitudinal hemodynamics in acute phase of treatment with labetalol in hypertensive pregnant women to predict need for vasodilatory therapy.
Topics: Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Infant, Low Birth Weight; Inf | 2017 |
Survey of healthcare professionals regarding adjustment of antihypertensive medication(s) in the postnatal period in women with hypertensive disorders of pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; General Practice; Guideline Adherence; Humans; Hype | 2016 |
Controversies Regarding Diagnosis and Treatment of Severe Hypertension in Pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Labetalol; Pre-E | 2017 |
Postpartum preeclampsia: emergency department presentation and management.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Antihypertensive Agents; Benzodiazepines; E | 2011 |
Stereoselective analysis of labetalol in human plasma by LC-MS/MS: application to pharmacokinetics.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Female; Humans; Labetalol; Molecular | 2009 |
[Anesthesia for the surgical removal of bilateral pheochromocytomas during the second trimester of pregnancy].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Anesthesia, Epidural; Anesthesia, Gene | 2009 |
Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Anima | 2009 |
Management of Takayasu arteritis during pregnancy.
Topics: Adult; Angiography; Antihypertensive Agents; Cesarean Section; Diagnosis, Differential; Female; Gluc | 2009 |
Folic acid uptake by the human syncytiotrophoblast: interference by pharmacotherapy, drugs of abuse and pathological conditions.
Topics: Amphetamine; Antihypertensive Agents; Atenolol; Biological Transport; Cell Survival; Cells, Cultured | 2009 |
Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings?
Topics: Adolescent; Adult; Antihypertensive Agents; Egypt; Female; Fetal Death; Fetal Monitoring; Gestationa | 2010 |
Association of preeclampsia and myasthenia: a case report.
Topics: Antihypertensive Agents; Cesarean Section; Cholinesterase Inhibitors; Female; HELLP Syndrome; Humans | 2009 |
Late postpartum preeclampsia with posterior reversible encephalopathy syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Antihypertensive Agent | 2009 |
Tonic-clonic seizures in a postpartum patient: case report.
Topics: Adult; Analgesics; Antihypertensive Agents; Diagnosis, Differential; Eclampsia; Epilepsy, Tonic-Clon | 2010 |
Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study.
Topics: Antihypertensive Agents; Attention; Attention Deficit Disorder with Hyperactivity; Bed Rest; Child; | 2010 |
[Pregnancy and advanced chronic kidney disease].
Topics: Ductus Arteriosus, Patent; Epilepsy; Female; Fetal Growth Retardation; Humans; Hyaline Membrane Dise | 2010 |
Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database.
Topics: Adult; Analysis of Variance; Child; Child Development; Child, Preschool; Databases, Factual; Female; | 2010 |
[HTA-pre-eclampsia-postpartum haemolytic-uraemic syndrome: good results can be achieved].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antihypertensive Agents; C | 2010 |
A case of hypertension with virilisation during pregnancy.
Topics: Adult; Aspirin; Brenner Tumor; Calcium; Cesarean Section; Dehydroepiandrosterone Sulfate; Dietary Su | 2010 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Adult; Amphetamine; Antihypertensive Agents; Cesarean Section; Chronic Disease; Cocaine; Cross React | 2011 |
Hypoglycaemia secondary to labetalol infusion.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypoglycemia; Infusions, Intravenous; Labetalol; Pre | 2011 |
Cardiovascular collapse after labetalol for hypertensive crisis in an undiagnosed pheochromocytoma during cesarean section.
Topics: Adrenal Gland Neoplasms; Adrenergic beta-Antagonists; Adult; Cesarean Section; Female; Humans; Hyper | 2011 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Amphetamine; Amphetamine-Related Disorders; Antihypertensive Agents; False Positive Reactions; Femal | 2011 |
Anaesthetic management of emergency caesarean section in a patient with seizures and likely raised intracranial pressure due to tuberculous meningitis.
Topics: Adult; Androstanols; Anesthesia, Obstetrical; Anesthetics, Inhalation; Anesthetics, Intravenous; Ant | 2011 |
Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia.
Topics: Algorithms; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension, Pregnancy-Induced; L | 2011 |
Neonatal side effects of maternal labetalol treatment in severe preeclampsia.
Topics: Adult; Antihypertensive Agents; Case-Control Studies; Female; Fetal Death; Humans; Infant Mortality; | 2012 |
Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Female; Humans; Hypertension, Pregnancy-Induc | 2012 |
Do not forget about HELLP!
Topics: Abortion, Spontaneous; Adult; Antihypertensive Agents; Eclampsia; Female; HELLP Syndrome; Humans; La | 2011 |
Fetal cardiac function after labetalol or pindolol for maternal hypertension in a sheep model of increased placental vascular resistance.
Topics: Animals; Antihypertensive Agents; Female; Fetal Heart; Hypertension, Pregnancy-Induced; Hypoxia; Lab | 2013 |
Is labetalol really a culprit in neonatal hypoglycaemia?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Female; Humans; Hypertension; Hypoglycemia; In | 2013 |
Raynaud's phenomenon of the nipple associated with labetalol use.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nipples; Pregnancy; Raynaud | 2013 |
Maternal antihypertensive drugs may influence cerebral oxygen extraction in preterm infants during the first days after birth.
Topics: Antihypertensive Agents; Case-Control Studies; Cerebral Cortex; Cerebrovascular Circulation; Female; | 2013 |
Postpartum eclampsia.
Topics: Adult; Anticonvulsants; Antihypertensive Agents; Diagnosis, Differential; Eclampsia; Female; Humans; | 2002 |
Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2002 |
[Influence of labetalol on the resistance of human fetoplacental vessels in perfusion in vitro].
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Dose-Response Relationship, Drug | 2002 |
Scleroderma renal crisis sine scleroderma during pregnancy.
Topics: Adult; Antihypertensive Agents; Arteries; Captopril; Drug Therapy, Combination; Female; Humans; Hype | 2003 |
Left ventricular diastolic function in pregnancy-induced hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Diastole; Echocardiography, Doppler; Female; Humans; Hypertensio | 2003 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance.
Topics: Adult; Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Fetus; Humans; Hydralazine | 2004 |
Nicardipine or labetalol as short-term treatment for severe hypertension of pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nicardipine; Pr | 2004 |
Renal cell carcinoma presenting as hypertension in pregnancy.
Topics: Adult; Antihypertensive Agents; Body Mass Index; Carcinoma, Renal Cell; Diagnosis, Differential; Fem | 2004 |
[Pregnancy and hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cesarean Section; Diagnosis, | 2005 |
Permanent visual deficits secondary to the HELLP syndrome.
Topics: Adult; Blood Pressure; Brain Infarction; Drug Therapy, Combination; Eclampsia; Female; Furosemide; H | 2005 |
Persistent visual loss after retinochoroidal infarction in pregnancy-induced hypertension and disseminated intravascular coagulation.
Topics: Adult; Antihypertensive Agents; Blindness; Choroid; Disseminated Intravascular Coagulation; Female; | 2005 |
Inadvertent intrathecal injection of labetalol in a patient undergoing post-partum tubal ligation.
Topics: Adult; Analgesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; Antihypertensive Agents; Bupi | 2005 |
The treatment of severe hypertension in pregnancy: a review of current practice and knowledge in West-Midlands maternity units.
Topics: Antihypertensive Agents; Female; Hospital Units; Humans; Hydralazine; Hypertension, Pregnancy-Induce | 2004 |
Magnesium sulphate therapy in women with pre-eclampsia and eclampsia in Kuwait.
Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Eclampsia; Fema | 2008 |
Beta-blockers for pregnancy hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy | 1983 |
Which beta-blocker in pregnancy-induced hypertension?
Topics: Atenolol; Birth Weight; Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Labetalol; Pre | 1983 |
[Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol].
Topics: Adrenergic beta-Antagonists; Adult; Ethanolamines; Female; Fetal Diseases; Humans; Hypertension; Hyp | 1984 |
Renin and aldosterone concentrations in pregnant essential hypertensives - a prospective study.
Topics: Adult; Aldosterone; Female; Humans; Hypertension; Labetalol; Methyldopa; Potassium; Pregnancy; Pregn | 1983 |
Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report.
Topics: Adult; Captopril; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension, Renovascular; | 1983 |
[New aspects in the therapy of pregnancy-induced hypertension].
Topics: Anesthesia, Epidural; Epoprostenol; Female; Fenoterol; Humans; Hypertension; Labetalol; Metoprolol; | 1983 |
Alternative mechanisms for the hypotensive effects of adrenergic blockade.
Topics: Epoprostenol; Ethanolamines; Female; Humans; Hypertension; Labetalol; Pregnancy | 1983 |
[Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases].
Topics: Adult; Apgar Score; Birth Weight; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newbor | 1984 |
Labetalol for the treatment of hypertension in pregnancy. Pharmacokinetics and effects on the uteroplacental blood flow.
Topics: Ethanolamines; Female; Humans; Hypertension; Kinetics; Labetalol; Placenta; Pregnancy; Pregnancy Com | 1984 |
Uteroplacental blood flow in pregnancy induced hypertension.
Topics: Blood Flow Velocity; Blood Pressure; Dihydralazine; Female; Fetal Heart; Heart Rate; Humans; Hyperte | 1984 |
Anaesthetic management of combined caesarean section and phaeochromocytoma removal.
Topics: Adrenal Gland Neoplasms; Adult; Anesthesia, General; Atenolol; Cesarean Section; Female; Humans; Lab | 1983 |
Side effects of labetalol in newborn infants.
Topics: Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Infant, Newborn, Diseases; Labetalol; | 1983 |
Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol.
Topics: Adolescent; Adult; Atenolol; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newborn; La | 1983 |
[Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol].
Topics: Adolescent; Adult; Atenolol; Delivery, Obstetric; Ethanolamines; Female; Fetal Heart; Fetal Monitori | 1983 |
Blood rheology in pre-eclampsia and intrauterine growth retardation: effects of blood pressure reduction with labetalol.
Topics: Adult; Bed Rest; Blood Pressure; Blood Viscosity; Ethanolamines; Female; Fetal Growth Retardation; H | 1984 |
Labetalol disposition and concentration-effect relationships during pregnancy.
Topics: Adolescent; Adult; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Injections, Intraven | 1983 |
Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy.
Topics: Adult; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Placenta; Pregnancy; Pr | 1982 |
The evaluation of labetalol in the treatment of hypertension complicating pregnancy.
Topics: Ethanolamines; Female; Fetus; Humans; Hypertension; Kidney; Labetalol; Liver; Milk, Human; Placenta; | 1982 |
Labetalol: the nineteen-eighties.
Topics: Adrenal Gland Neoplasms; Anesthesia; Coronary Disease; Ethanolamines; Female; Humans; Hypertension; | 1982 |
Acute effect of an antihypertensive drug, labetalol, on uteroplacental blood flow.
Topics: Blood Pressure; Depression, Chemical; Ethanolamines; Female; Heart Rate; Humans; Indium; Labetalol; | 1982 |
Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.
Topics: Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Lipid Metabolism | 1981 |
Observations on the effect of labetalol on pregnancy and parturition in normotensive rats.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Ethanolamines; Female; Labetalol; Labor, | 1980 |
Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy.
Topics: Adult; Eclampsia; Female; Glucagon; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, Disease | 1995 |
Warfarin embryopathy: patient, possibility, pathogenesis and prognosis.
Topics: Acenocoumarol; Bone and Bones; Developmental Disabilities; Drug Combinations; Female; Fetal Diseases | 1993 |
The effect of labetalol on maternal haemodynamics and placental perfusion in awake near term guinea pigs.
Topics: Animals; Female; Gestational Age; Guinea Pigs; Hemodynamics; Labetalol; Placenta; Pregnancy; Regiona | 1995 |
The effects of dihydralazine, labetalol and magnesium sulphate on the isolated, perfused human placental cotyledon.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Dihydralazine; Dose-Response Rel | 1994 |
Heart rate and heart rate variability during sleep in small-for-gestational age newborns.
Topics: Basal Metabolism; Birth Weight; Female; Fetal Growth Retardation; Gestational Age; Heart Rate; Human | 1994 |
[Subcapsular liver hematoma, a HELLP syndrome complication].
Topics: Adult; Cesarean Section; Combined Modality Therapy; Female; HELLP Syndrome; Hematoma; Humans; Labeta | 1994 |
Acute exercise- and drug-induced potassium shifts during pregnancy.
Topics: Adult; Exercise; Exercise Test; Female; Humans; Hypertension; Labetalol; Potassium; Pregnancy; Refer | 1994 |
Effect of labetalol infusion on uterine and fetal hemodynamics and fetal cardiac function.
Topics: Blood Pressure; Female; Fetal Heart; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Lab | 1993 |
Neonatal adrenergic blockade following single dose maternal labetalol administration.
Topics: Adult; Bradycardia; Diseases in Twins; Female; Fetal Blood; Humans; Hypoglycemia; Hypotension; Infan | 1994 |
Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis.
Topics: Adult; Apgar Score; Birth Weight; Blood Pressure; Drug Administration Schedule; Female; Gestational | 1993 |
Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration.
Topics: Animals; Blood Gas Analysis; Female; Hemodynamics; Injections, Intravenous; Labetalol; Lactates; Pla | 1993 |
Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome.
Topics: Adult; Female; Fetus; Humans; Labetalol; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy Complications | 1993 |
Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment.
Topics: Adolescent; Adult; Female; Fetal Hypoxia; Hemodynamics; Humans; Hydralazine; Infant, Newborn; Labeta | 1993 |
Effects of labetalol on uterine blood flow and cardiovascular hemodynamics in the hypertensive gravid baboon.
Topics: Animals; Female; Hemodynamics; Hypertension; Iliac Artery; Labetalol; Papio; Pregnancy; Pregnancy Co | 1993 |
Transverse limb deficiency, facial clefting and hypoxic renal damage: an association with treatment of maternal hypertension?
Topics: Abnormalities, Drug-Induced; Adult; Child, Preschool; Facial Bones; Female; Fetal Death; Fetus; Huma | 1995 |
The calcium-dependent nitric oxide production of human vascular endothelial cells in preeclampsia.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Calcimycin; Calcium; Cell Count; Cells, Cultur | 1996 |
Effects of antihypertensive drugs on maternal and fetal hemodynamics and uterine blood flow in pregnant goats--comparison of nicardipine and labetalol.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbon Dioxide; Female; Fetal Blood; Fetus; Goats; | 1996 |
Phenoxybenzamine placental transfer during the third trimester.
Topics: Adrenal Gland Neoplasms; Adult; Antihypertensive Agents; Female; Fetal Blood; Humans; Hypertension; | 1996 |
The role of labetalol and propofol in the management of HELLP syndrome--a case report.
Topics: Adult; Anesthetics, Intravenous; Antihypertensive Agents; Female; HELLP Syndrome; Humans; Labetalol; | 1996 |
Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states.
Topics: Antihypertensive Agents; Cohort Studies; Embryo, Mammalian; Embryonic and Fetal Development; Female; | 1998 |
Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis.
Topics: Adolescent; Female; Fetal Diseases; Heart Rate, Fetal; Humans; Hypertension; Infant, Newborn; Infant | 1998 |
Adverse neonatal effects of maternal labetalol treatment.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Cardiomegaly; Dobutamine; Dopamine; Dr | 1998 |
Changes in maternal middle cerebral artery blood flow velocity associated with general anesthesia in severe preeclampsia.
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Antihypertensive Agents; Blood Flow Velocity; | 1999 |
Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus.
Topics: Azathioprine; Cesarean Section; Cyclosporine; Fatal Outcome; Female; Graft Rejection; Humans; Hypert | 1999 |
Transplacental distribution of labetalol stereoisomers at delivery.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Labor, Obstetric; Maternal- | 1999 |
Recurrent cholestasis following ovarian hyperstimulation syndrome: case report.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Cholestasis; Female; Fertilization in Vitro; Gesta | 1999 |
Magnesium sulphate for pre-eclampsia and a sudden bradycardia.
Topics: Adolescent; Adrenergic beta-Antagonists; Bradycardia; Calcium Channel Blockers; Drug Interactions; F | 2000 |
A case of renovascular hypertension due to bilateral renal artery microaneurysm who succeeded in baby delivery.
Topics: Adrenergic beta-Antagonists; Adult; Aneurysm; Angiography; Female; Humans; Hypertension, Renovascula | 2001 |
Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Fetal Blood; Gestational Age; Humans; Hyperten | 2000 |
Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension.
Topics: Antihypertensive Agents; Apgar Score; Cesarean Section; Comorbidity; Disease Susceptibility; Female; | 2001 |
Guidelines on high blood pressure in pregnancy give new classifications of disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Contra | 2000 |
Labetalol possesses beta-adrenoceptor agonist action on the rat isolated uterus.
Topics: Adrenergic beta-Agonists; Animals; Estrus; Ethanolamines; Female; In Vitro Techniques; Isoproterenol | 1979 |
Use of labetalol in the treatment of severe hypertension during pregnancy.
Topics: Adolescent; Adult; Amniotic Fluid; Birth Weight; Ethanolamines; Female; Fetal Blood; Humans; Hyperte | 1979 |
Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.
Topics: Administration, Oral; Anesthesia; Angina Pectoris; Catecholamines; Ethanolamines; Female; Hemodynami | 1979 |
The cardiovascular and uterine effects of labetolol in conscious normotensive pregnant rats [proceedings].
Topics: Animals; Ethanolamines; Female; Hemodynamics; Labetalol; Pregnancy; Rats; Uterine Contraction | 1977 |
The treatment of hypertension in pregnancy.
Topics: Adolescent; Adult; Anticonvulsants; Antihypertensive Agents; Bethanidine; Eclampsia; Female; Humans; | 1978 |
Metabolism of labetalol by animals and man.
Topics: Administration, Oral; Animals; Autoradiography; Blood Proteins; Chromatography, Ion Exchange; Chroma | 1976 |
Affinity of labetalol for ocular melanin.
Topics: Administration, Oral; Animals; Cats; Cornea; Dogs; Dose-Response Relationship, Drug; Drug Evaluation | 1976 |
Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Cardiac Output; Creatinine; Drug Admi | 1976 |
The metabolism of labetalol in animals and man.
Topics: Administration, Oral; Animals; Chromatography, Thin Layer; Dogs; Ethanolamines; Female; Glucuronates | 1976 |
Effects of maternal labetalol on the newborn infant.
Topics: Asphyxia Neonatorum; Female; Fetal Growth Retardation; Humans; Hypertension; Hypoglycemia; Incidence | 1992 |
Fetal death following labetalol administration in pre-eclampsia.
Topics: Adult; Cesarean Section; Female; Fetal Death; Humans; Labetalol; Pre-Eclampsia; Pregnancy; Premedica | 1992 |
Hemodynamic collapse following labetalol administration in preeclampsia.
Topics: Adult; Cesarean Section; Female; Humans; Hypotension; Labetalol; Pre-Eclampsia; Pregnancy; Premedica | 1992 |
Pharmacokinetics/pharmacodynamics of labetalol in three pregnant ewes using high-performance liquid chromatography.
Topics: Animals; Chromatography, High Pressure Liquid; Female; Fetus; Hemodynamics; Labetalol; Pregnancy; Pr | 1992 |
Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep.
Topics: Animals; Blood Glucose; Blood Pressure; Carbon Dioxide; Female; Labetalol; Lactates; Lactic Acid; Ox | 1992 |
Maternal and fetal effects of labetalol in pregnant ewes.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Female; | 1991 |
Response to beta-blockers in maternal and fetal rat hearts in vitro.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Female; Heart; Heart Rate; Isoproterenol; Labetalol; | 1991 |
Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Female; Fetus; Heart Rate; Heart Rate, Fetal; Hemodynami | 1991 |
Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol.
Topics: Female; Heart Rate, Fetal; Hemodynamics; Humans; Hydralazine; Hypertension; Labetalol; Pregnancy; Pr | 1991 |
Sensitive microbore high-performance liquid chromatographic assay for labetalol in the biological fluids of pregnant sheep.
Topics: Amniotic Fluid; Animals; Chromatography, High Pressure Liquid; Female; Fetal Blood; Fetus; Injection | 1991 |
Postpartum amaurosis.
Topics: Adult; Blindness; Emergency Service, Hospital; Female; Humans; Labetalol; Magnetic Resonance Imaging | 1991 |
Effects of vasodilators on isolated human uteroplacental arteries.
Topics: Angiotensin II; Arteries; Chorionic Villi; Dinoprost; Female; Humans; Hydralazine; Labetalol; Nitren | 1991 |
Single dose of labetalol in normotensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Drug Administration Schedule; Female; Fetus; Gestational | 1991 |
Labetalol pharmacokinetics in pregnancy-induced hypertension.
Topics: Adolescent; Adult; Amniotic Fluid; Female; Fetal Blood; Humans; Hypertension; Labetalol; Metabolic C | 1990 |
Severe adverse effects of maternal labetalol in a premature infant.
Topics: Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Labetalol; Maternal-Fetal Exchange; Pr | 1989 |
Half-life of maternal labetalol in a premature infant.
Topics: Adult; Female; Half-Life; Humans; Hypertension; Infant, Newborn; Infant, Premature; Labetalol; Male; | 1989 |
Hypertensive and catecholamine response to tracheal intubation in patients with pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Cesarean Section; Female; Heart Rate; Humans; Hypertension; Intubation, Intra | 1989 |
[Effects of beta-adrenoceptor blockade on parturition and fetal cardiovascular and metabolic system].
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Blood Glucose; Ethanolamines; Female; Fetal Death; | 1985 |
[Hypertension in pregnancy: proposed monitoring and therapy].
Topics: Adrenergic beta-Antagonists; Captopril; Diuretics; Female; Follow-Up Studies; Humans; Hydralazine; H | 1985 |
The effect of labetalol on contractility of human myometrial preparations.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; | 1987 |
Placental transfer of beta-adrenergic antagonists studied in an in vitro perfusion system of human placental tissue.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Female; Humans; In Vitro Techniques; Labetalol; M | 1988 |
Beta blockers inhibit fetal thromboxane A2 production in vitro.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Platelets; Female; Fetal Blood; Humans; Infant, Newborn | 1988 |
Labetalol does not decrease placental perfusion in the hypertensive term-pregnant rat.
Topics: Animals; Female; Genitalia, Female; Hemodynamics; Hypertension; Labetalol; Muscles; Placenta; Pregna | 1989 |
[Labetalol in the treatment of pregnancy arterial hypertension. 70 cases].
Topics: Adult; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Complications, Cardiovascular | 1986 |
[Therapeutic monitoring of hypertensive syndrome in pregnancy].
Topics: Adult; Female; Humans; Hypertension; Labetalol; Monitoring, Physiologic; Pregnancy; Pregnancy Compli | 1988 |
A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term.
Topics: Female; Hospitalization; Humans; Labetalol; Pre-Eclampsia; Pregnancy | 1988 |
Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia.
Topics: Blood Pressure; Epoprostenol; Female; Fetus; Heart Rate; Hemodynamics; Humans; Labetalol; Placenta; | 1986 |
Fetal haemodynamics before and after treatment of maternal hypertension in pregnancy.
Topics: Blood Flow Velocity; Female; Fetus; Hemodynamics; Humans; Hypertension; Labetalol; Maternal-Fetal Ex | 1987 |
Platelet function in pregnancy induced hypertension following treatment with labetalol and low dose aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Collagen; Dose-Response Relationship, Drug; | 1987 |
The effect of maternal labetalol on the newborn infant.
Topics: Blood Pressure; Female; Humans; Infant, Newborn; Labetalol; Maternal-Fetal Exchange; Oxygen Consumpt | 1986 |
Transfer of labetalol into amniotic fluid and breast milk in lactating women.
Topics: Amniotic Fluid; Female; Humans; Hypertension; Labetalol; Lactation; Milk, Human; Pregnancy; Pregnanc | 1985 |